

Enabling Synthesis in Fragment-based Drug Discovery (FBDD): Microscale High-throughput Optimisation of the Medicinal Chemist's Toolbox Reactions

Chloe Townley, Davide Branduardi, Gianni Chessari, Benjamin D. Cons, Charlotte Griffiths-Jones, Richard J. Hall,
Christopher N. Johnson, Yuji Ochi, Stuart Whibley, and Rachel Grainger*

Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA.

General Experimental Information.....	1
Equipment used in this study	2
Chronect Quantos, Mettler-Toledo balance and dosing heads	2
Aluminium reaction blocks, glass vials, stir bars and stir bar dispenser	4
Validation work for screening kits	5
Selection of glass bead size	5
Dosing accuracy inorganic bases	6
Pd-ChemBead preparation	7
Dosing accuracy Pd-ChemBeads.....	8
Glass bead spacers.....	9
Reaction solvent evaporation.....	10
Comparing Pd-ChemBeads to pure Pd-catalysts	11
Astex preferred reaction conditions from electronic lab notebook (ELN)	12
Suzuki-Miyaura cross-coupling	12
Buchwald-Hartwig Amination.....	14
SNAr.....	16
Screening plate information	17
Kit prep	17
Suzuki-Miyaura screening kit.....	18
Buchwald Primary amine screening kit	19
Buchwald Secondary amine and aniline screening kit.....	20
Buchwald amide and oxygen screening kit.....	21
SNAr screening kit	22
Setting up the screening kits	23
Creation of the analytical plates for MISER	23

Suzuki-Miyaura Cross-coupling screening plate; 5-bromo-1H-pyrrolo[2,3-b]pyridine and (2-fluorophenyl)boronic acid	25
Buchwald primary amine screening plate (unhindered primary amine); 5-bromo-1H-pyrrolo[2,3-b]pyridine and 1-(pyridin-4-yl)methanamine	26
Buchwald primary amine screening plate (hindered primary amine); 5-bromoisoquinoline and 2-phenylpropan-2-amine	27
Buchwald secondary amine / aniline screening plate (secondary amine); 5-bromo-1H-pyrrolo[2,3-b]pyridine and tert-butyl piperazine-1-carboxylate	28
Buchwald secondary amine / aniline screening plate (aniline); 5-bromo-1H-pyrrolo[2,3-b]pyridine and 5-methoxypyridin-2-amine	29
Buchwald amide and oxygen screening kit (amide); 1-bromo-4-methoxybenzene and pyridine-3-carboxamide	30
Buchwald amide and oxygen screening kit (oxygen); 6-chloroquinoline and tert-butyl 3-hydroxyazetidine-1-carboxylate	31
S_NAr screening plate:	32
Batch scale-up reactions and characterization data.....	33
5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine (3).....	33
<i>N</i> -[(pyridin-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-amine (4)	34
<i>N</i> -(2-phenylpropan-2-yl)isoquinolin-5-amine (5)	35
5-methoxy- <i>N</i> -{1H-pyrrolo[2,3-b]pyridin-5-yl}pyridin-2-amine (10).....	37
<i>N</i> -(4-methoxyphenyl)pyridine-3-carboxamide (11).....	38
methyl 7-(benzyloxy)-1H-indazole-4-carboxylate (15)	40
Experimental References.....	40
NMR spectra	41
Tabulated MISER data:	50
Suzuki-Miyaura screening kit.....	50
Buchwald-Hartwig primary amine screening kit (primary amine).....	55
Buchwald-Hartwig primary amine screening plate (sterically hindered primary amine)	60
Buchwald-Hartwig secondary amine and aniline screening kit (secondary amine)	67
Buchwald secondary amine and aniline screening kit (aniline).....	73
Buchwald amide and oxygen screening kit (amide)	78
Buchwald amide and oxygen screening kit (oxygen).....	83
S_NAr screening kit	89

General Experimental Information

Millimolar scale reactions carried out in Analytical Sales 96 well Para-dox® Aluminium Reaction Blocks with 1 mL glass vials containing stirrer bars. Reactions were performed with exclusion of air, unless otherwise stated. This was achieved by using solvent that had been sparged with N₂ for 15 mins and by purging the headspace of the reaction vial with a positive pressure of N₂ and an outlet needle. Commercial solvents and reagents were used without further purification.

Flash column chromatography was performed on a Biotage SP1 system; normal-phase chromatography performed with silica Sfar columns (32–63 µm particle size, KP-Sil, 60 Å pore size) and the stated solvent system (n.b. Petrol refers to Petroleum Ether bp 40–60 °C).

MISER Acquisition: Reversed phase HPLC experiments were performed on an Agilent 1290 Infinity II system. The Agilent stack was comprised a G7120A high speed pump, G7167B multisampler, G7116B multicolour thermostat, G7117B diode array detector and a 6135 Quadrupole LC/MSD XT detector with multimode ionization. The system was controlled by OpenLab CDS Chemstation Edition software, with the FIA mode enabled. Separations were carried out on a 2.0 mm i.d. by 30 mm length, 1.9 µm YMC-Triart C18 column by isocratic elution at a flow rate of 1.5 mL/min. The LC eluents were 16% solvent A (10 mM ammonium acetate in H₂O, pH 6.8) and 84% solvent B (acetonitrile). The column was maintained at a temperature of 40 °C. The MISERgrams were obtained from continuous sample injections (0.5 µL) every 12.5s. The multimode ESI+APCI parameters were fragmentor 60 V, desolvation gas (N₂) temperature 350 °C and flow rate 12 L/min, vaporizer temperature 250 °C, the nebulizer was adjusted to 35 psi, the capillary voltage to 3000 V and the corona current to 1µA.

Batch reactions were monitored by LC-MS using an Agilent 1290 Infinity II series UHPLC coupled to an Agilent 6130 single quadrupole mass detector, eluting a gradient of 3-95% (MeCN in H₂O, 0.1% HCO₂H modifier) over 0.93 minutes run on a YMC-Triart C18 50x2.0mm 1.9µm column controlled at 40 °C, or a Shimadzu Nexera UHPLC coupled to a Shimadzu LCMS-2020 single quadrupole mass detector. High resolution mass spectrometry was performed on an Agilent 6550 QTOF mass spectrometer.

NMR spectra were recorded on a Bruker AV400 (Avance 400 MHz) spectrometer. Chemical shifts for ¹H and ¹³C NMR spectra are reported as δ in units of parts per million (ppm) and quoted to the nearest 0.01 ppm relative to the residual protons in CDCl₃ (7.26 ppm, 77.16 ppm), d₆-DMSO (2.50 ppm, 39.52 ppm) or CD₃OD (3.31 ppm, 49.00 ppm). Coupling constants (J) are quoted in Hertz (Hz) and are reported to the nearest 0.1 Hz, with multiplicity reported according to the following convention: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad and associated combinations e.g., dd = double of doublets. DEPT 135 and 2-dimensional experiments (COSY, HMBC, HSQC and ROESY) were used to support assignments and are reported where appropriate.

Equipment used in this study

Chronect Quantos, Mettler-Toledo balance and dosing heads

All solid dosing was achieved using the Chronect Quantos platform from Axel Semrau. The platform utilises a Mettler-Toledo balance system coupled with a Universal Robots UR3 cobot, which is a 6-axis robotic arm capable of transporting vials, dosing heads and balance adaptors. Up to 32 solids may be stored in dosing heads which are held in a rack at the back of the platform and all data pertaining to the solids is stored in an RFID tag which can be read by the balance. Finally, the Chronect Quantos is equipped with a three-position deck capable of holding the analytical sales Para-dox aluminium reaction blocks.




Figure S1: A photograph of our Chronect Quantos platform, with all the components highlighted, featuring a Mettler-Toledo balance, Universal Robots UR3 and analytical sales Para-dox aluminium reaction blocks.

There are several commercially available dosing heads available to purchase through Mettler-Toledo. The three investigated in this work for their compatibility with our Chronect Quantos and ChemBead selection can be seen below (figure S2). The so called ‘normal’ dosing head (QH012-LNMW) is a standard dosing head for up to 125 mL of material with a 2.5 mm dosing pin diameter. The antistatic dosing head (QH010-CN MW) is a standard dosing head with a 2.5 mm dosing pin diameter. The final dosing head investigated is a ‘Pinocchio’ dosing head (QH008-BNMP), so called as it has a 1mm nose which extends into the top of the vial while the substance is dispensed. This dosing head also has a 2.5 mm dosing pin diameter.

Table S1: The components, suppliers and serial numbers required to assemble the screening kits.

Supplier	Component	Serial number
Analytical Sales	96-Well Parallel Synthesis/Optimization Block Assembly	96960
	Replacement PFA Films for 96-Well Blocks	96967
	Replacement Rubber Mats for 96-Well Block Assemblies	96965
	Stackable Tray with 8x30 Shell Vials	884001
	Stir Bars for Photoredox & Parallel Synthesis (gold) Block Systems	13258
Thistle Scientific (formally VP Scientific)	Drop Dispenser, for VP 711 series Tumble Stir Elements	VPS-VP711A-96-AS-1
Sigma-Aldrich	Glass beads, acid-washed, $\leq 106 \mu\text{m}$ (-140 U.S. sieve)	G4649
	Glass beads, acid-washed, 150-212 μm (70-100 U.S. sieve)	G1145




Figure S2: The three dosing heads investigated in the study for

their compatibility with our Chronect Quantos and chembead selection. The dosing heads include the 'normal' dosing head (QH012-LNMW), antistatic dosing head (QH010-CNMW) and the 'Pinocchio' dosing head (QH008-BNMP).

Aluminium reaction blocks, glass vials, stir bars and stir bar dispenser

The consumable components for the screening kits can be seen below (figure S3). Analytical sales Para-dox blocks are loaded with 1 mL glass vials (884001). Stir bars (13258) are loaded into every vial using a Drop Dispenser (VPS-VP711A-96-AS-1). Finally, two rubber mats and a new PFA film are added to the lid. A table of the components, suppliers and serial numbers can be found below.




Figure S3: The consumable components used to facilitate the production of the screening kits. An Analytical sales Para-dox plate loaded with 1 mL glass vials containing a stir bar and the lid with a new PFA film in place.

Validation work for screening kits

Selection of glass bead size

Multiple glass bead sizes were available from Sigma, we investigated 150-212 µm (G1145) and ≤106 µm (G4649) in two types of dosing head to start with, the ‘normal’ dosing head (QH012-LNMW) and the antistatic dosing head (QH010-CNMMW). Initially, when coated in a test substrate (Copper Iodide) it appears the smaller glass beads are generally dosed more accurately (figure S4).




Figure S4: Dosing test to assess the suitability of Cul-ChemBeads, with a 1 mg target weight per dose. Here the percentage deviation (the % over the target dose) is plotted for every vial dosed. Each combination was dosed into 24 (two rows) of glass vials. The blue box denotes the pre-set tolerance window (+/- 10%) on the Chronect Chronos software. Even on a small scale, dosing is constant and largely within the window of +/-10% deviation.

Dosing accuracy inorganic bases

Inorganic bases were milled to a fine powder prior to use in a Resodyn Acoustic Mixer LabRAM1, using stainless steel milling beads [Fisherbrand™ Bulk Beads; 15505809], and the protocol described by Abbvie¹. Representative pictures of milled bases are shown below, beads were removed afterwards with a PTFE stir bar retriever. Some clumping is observed with hygroscopic bases, prior to use these bases are dried in a heated vacuum desiccator and stored in a glovebox. No visible difference observed between 10 and 20 mins.




Figure S5: Photograph comparison of four different inorganic bases (K_2CO_3 , CsF , Cs_2CO_3 and K_3PO_4) before milling, and after milling at 40 g for 10 mins and 40 g for 20 mins.




Figure S6: Assessing the dosing accuracy of milled inorganic bases with repeated dosing of K_2CO_3 (2.76 mg), K_3PO_4 (4.25 mg), CsF (3.04 mg), NaOH (0.80 mg). Even on a small scale, dosing is remarkably constant and largely within a window of 10% deviation.

Pd-ChemBead preparation

Palladium catalysts were not milled prior to glass bead coating as milling caused the catalyst powders to adhere to the sides of the glass vials. If catalyst powders are gritty or clumpy, milling beads can be added to the vials during the coating process.

Compared to the procedure reported by AbbVie¹, a modified procedure was used.




Figure S7: A schematic detailing the procedure used to make the Pd-coated ChemBeads and a photograph of the ChemBeads prepared for the Suzuki-Miyaura screening kit.

¹ Noah P. Tu, Dr. Amanda W. Dombrowski, Dr. Gashaw M. Goshu, Dr. Anil Vasudevan, Dr. Stevan W. Djuric, Dr. Ying Wang, Angew. Chem. Int. Ed. 2019, 7987.

Dosing accuracy Pd-ChemBeads

The repeated dosing accuracy of the Chronect Quantos was tested with all 12 of the Palladium-ChemBeads required for a Suzuki screening plate (figure S8). The target dose for each palladium catalyst can be found in a later section detailing the procedure for kit preparation. Again, the dosing results are remarkably consistent, with only one vial requiring a top up to reach the minimum required amount for the reaction. Typically, we do not correct any doses which exceed the +10% deviation.





Figure S8: Assessing the dosing accuracy of Pd-ChemBeads with repeated dosing (x8) of 12 different Pd-ChemBeads. Even on a small scale, dosing is constant and largely within a window of +10% deviation. Only one dose failed to reach the minimum amount required [1.62 mg (actual) vs 1.69 mg (required)].


Glass bead spacers

Ideally, we wanted to control when the palladium catalyst and base come into contact to prevent any risk of catalyst decomposition. Cs_2CO_3 and Cul (5 wt%) ChemBeads were used to investigate the weight of glass beads required to keep the two components separate due to the clear colour change when they react. From our investigations it is clear ≥ 50 mg of glass beads is required to keep the two components separate (Figure S9).


Cs_2CO_3 then beads (150-200 μm) then Cul 5% <100 μm



Cs_2CO_3 then beads (150-200 μm) then Cul 5% <100 μm



Cul 5% <100 μm , beads (150-200 μm) then Cs_2CO_3



Cul 5% <100 μm , beads (150-200 μm) then Cs_2CO_3




Figure S9: Investigation into the weight of glass beads to act as a spacer to keep Cs_2CO_3 and Cul (5 wt%) ChemBeads apart. A clear colour change can be seen (colourless to blue) when they react.

Reaction solvent evaporation

Despite sealing according to the manufacturer's instructions, solvent evaporation still occurs within the plate. Two representative examples of solvent loss are shown below. Despite being heated *c.a.*20 °C below the boiling point of these solvents, evaporation of a number of wells occurs. This is typically less than 10% of reaction vials. In these wells the appropriate solvent (100 µL) is added then the whole block is stirred again for 5 min to ensure all samples are in solution for the creation of the analytical plates.





Figure S10: Schematic detailing the solvent evaporation observed from two screening kits. Less than 10% of the wells had no solvent left in them.

Comparing Pd-ChemBeads to pure Pd-catalysts

Before their use in a screening kit, we wanted to ensure the Pd-ChemBeads were comparable to commercially available, powdered catalyst. The Pd(dppf)Cl₂ ChemBeads (two bed sizes) and powdered catalyst were compared heat-to-head in two test reactions and can be seen below (figure S11). In each case the Chembeads and powdered catalysts proved equivalent, with the same conversion achieved in each test reaction.



*Based on LCAP

Reactions 5 and 6 were repeated again in quadruplicate (8 reactions in total) and >95% conversion was observed by LCAP in each case.



Figure S11: Comparison between powdered catalyst and the manufactured ChemBeads (two bead sizes). In all cases the ChemBeads and powdered catalysts performed equally.

Astex preferred reaction conditions from electronic lab notebook (ELN)

The most common experimental conditions (catalyst, base, and solvent) have been extracted from Astex's electronic lab notebook for the cross-coupling reactions investigated by the screening plates.

Suzuki-Miyaura cross-coupling

The ELN data was extracted in Feb 2021 with only successful reactions were included in this analysis. 888 entries were found for catalysts for the Suzuki-Miyaura reaction, 963 entries relating to bases and 942 entries relating to solvent systems. From the extracted ELN data the most commonly used catalyst, base and solvent system is as follows; $\text{Pd}(\text{PPh}_3)_4$, K_2CO_3 and dioxane–water.



**Solvent used in Suzuki-Miyaura Cross-coupling
data, Feb 2021), 942 entries**

(Astex ELN






Figure S12: The most commonly used experimental conditions within the ELN for the Suzuki-Miyaura cross coupling reaction. A - the most commonly used catalyst, B - the most commonly used bases and C - the most commonly used solvent systems.

Buchwald-Hartwig Amination

The ELN data was extracted in Oct 2021 with only successful reactions were included in this analysis. 655 entries were found for catalysts for the Suzuki-Miyaura reaction, 641 entries relating to bases and 764 entries relating to solvent systems. From the extracted ELN data the most commonly used catalyst, base and solvent system is as follows; ^tBuXPhos, t-BuONa and dioxane.






Figure S13: The most commonly used experimental conditions within the ELN for the Buchwald-Hartwig cross coupling reaction. A - the most commonly used catalyst, B - the most commonly used bases and C - the most commonly used solvent systems.

S_NAr

The ELN data was extracted in Oct 2022, with only successful reactions were included in this analysis. 1092 entries were found for additives for successful nucleophilic aromatic substitution reactions, 1092 entries relating to bases and additives, and 816 entries relating to solvent systems. From the extracted ELN data the most commonly used additive and solvent system is as follows; DIPEA and DMSO.




Figure S14: The most commonly used experimental conditions within the ELN for the Nucleophilic Aromatic Substitution (S_NAr) reaction. A - the most commonly used base/additive, B - the most commonly used solvent systems.

Screening plate information

Kit prep

The consumable components for the screening kits are assembled before they are placed on the Chronect Quantos platform for dosing. The analytical sales Para-dox blocks are loaded with 1 mL glass vials (884001). Quick loading of the vials is achieved by inverting the vials into an empty stackable tray (vials are now up-side down and this is repeated into the Para-dox block. Stirrer bars (13258) are loaded into every vial using a Drop Dispenser (VPS-VP711A-96-AS-1). Finally, two rubber mats and a new PFA film are added to the lid.

On completion of the solid dosing, the vials contain a stir bar, base, glass bead spacer and Pd-catalyst with the order depicted below (with the exception of the S_NAr plate). The plates are sealed as per the manufacturer's instructions, then stored in Mylar bags (34 cm × 24 cm) with a 300cc oxygen absorber (both purchased from mylrbags.com). They can then be stored in the freezer until required.





Figure S15: A schematic showing the components in the vials upon completion of solid dosing.

When the kit is required, it can be removed from the freezer and allowed to warm up to room temperature before the mylar bag is opened. Liquid reagents and starting material stock solutions can then be added to the plate using the procedure detailed below.

Suzuki-Miyaura screening kit

The plate design for the Suzuki-Miyaura screening plate can be seen below. An Analytical Sales 96 well Para-dox® Aluminium Reaction Block was dosed with all solid reagents using the Chronect Quantos (Axel Semrau, Germany). The order of addition was as follows; solid base, glass bead spacer and ChemBeads (glass beads coated in palladium pre-catalyst, 10 wt% unless otherwise stated). The addition of the coupling partners follows the procedure listed below.




Reagent	FW (gmol ⁻¹)	Loading (equiv)	Mass (mg)	ChemBead loading	Mass (mg)
SPhos-Pd-G3	780.33	0.02	0.156	10.0%	1.56
DTBPF-Pd-G3	844.24	0.02	0.169	10.0%	1.69
cataCXium A-Pd-G3	728.35	0.02	0.146	10.0%	1.46
XPhos-Pd-G3	846.54	0.02	0.169	10.0%	1.69
APhos-Pd-G3	635.17	0.02	0.127	5.0%	2.54
RuPhos-Pd-G4	850.4	0.02	0.170	10.0%	1.70
BrettPhos-Pd-G3	906.6	0.02	0.181	10.0%	1.81
P(t-Bu) ₃ -Pd-G4	568.08	0.02	0.114	10.0%	1.14
PCy ₃ -Pd-G4	664.26	0.02	0.133	10.0%	1.33
DavePhos-Pd-G3	763.35	0.02	0.153	5.0%	3.05
Pd(dppf)Cl ₂	731.73	0.02	0.146	5.0%	2.93
IPr(η ³ -indenyl)PdCl	702.81	0.02	0.141	10.0%	1.34
K ₂ CO ₃	138.21	2.0	2.76	n/a	n/a
K ₃ PO ₄	212.27	2.0	4.25	n/a	n/a
CsF	151.91	2.0	3.04	n/a	n/a
NaOH	18.02	2.0	0.80	n/a	n/a

Figure S16: The plate design and the target dose for each component for the Suzuki-Miyaura screening plate.

Buchwald Primary amine screening kit

The plate design for the primary amine Buchwald screening plate can be seen below. An Analytical Sales 96 well Para-dox® Aluminium Reaction Block was dosed with all solid inorganic bases using the Chronect Quantos (Axel Semrau, Germany). The organic bases were added as neat solutions using the procedure listed below and the addition of the coupling partners follows the procedure listed below.




Reagent	FW (gmol ⁻¹)	Loading (equiv)	Mass (mg)	ChemBead loading	Mass (mg)
DMPDAB Pd-MAH	468.84	0.02	0.094	10.0%	0.94
Ad-BippyPhos	662.84	0.02	0.133	10.0%	1.33
MorDal-Phos-Pd-G4	847.48	0.02	0.169	10.0%	1.69
JosiPhos-Pd-G3	926.40	0.02	0.185	10.0%	1.85
t-BuBrettPhos-Pd-G3	856.54	0.02	0.171	10.0%	1.71
BrettPhos-Pd-G4	906.60	0.02	0.181	10.0%	1.81
[BippyPhos-Pd(η^3 -allyl)]OTf	803.19	0.02	0.161	10.0%	1.61
Me ₃ (OMe)t-BuXPhos-Pd-G3	822.52	0.02	0.165	10.0%	1.65
AdBrettPhos-Pd-G3	1010.76	0.02	0.202	10.0%	2.02
(t-Bu)PhCPhos-Pd-G4	788.36	0.02	0.158	10.0%	1.58
PhCPhos	424.56	0.02	0.085	5.0%	1.70
PEPPSI IPr	681.54	0.02	0.136	10.0%	1.36
GPhos-Pd-G3	906.50	0.02	0.181	10.0%	1.81
t-BuOK	112.23	2.0	2.24	n/a	n/a
KHMDS	199.53	2.0	3.99	n/a	n/a
Cs ₂ CO ₃	325.83	2.0	6.52	n/a	n/a
P2-Et	339.48	2.0	6.79	n/a	n/a

Figure S17: The plate design and the target dose for each component for the Buchwald-Hartwig primary amine screening plate.

Buchwald Secondary amine and aniline screening kit

The plate design for the secondary amine Buchwald screening plate can be seen below. An Analytical Sales 96 well Para-dox® Aluminium Reaction Block was dosed with all solid inorganic bases using the Chronect Quantos (Axel Semrau, Germany). The organic bases were added as neat solutions using the procedure listed below and the addition of the coupling partners follows the procedure listed below.




Reagent	FW (gmol ⁻¹)	Loading (equiv)	Mass (mg)	ChemBead loading	Mass (mg)
^{DMP} DAB-Pd-MAH	468.84	0.02	0.094	10.0%	0.94
QPhos-Pd-G3	1080.44	0.02	0.216	10.0%	2.16
PEPPSI IPr	681.54	0.02	0.136	10.0%	1.36
Triisobutylphosphatrane (6)	342.58	0.02	0.137 [‡]		
RuPhos-Pd-G4	850.40	0.02	0.170	10.0%	1.70
[BippyPhos-Pd(η ³ -allyl)]OTf	803.19	0.02	0.161	10.0%	1.61
t-BuXPhos-Pd-G3	794.46	0.02	0.159	10.0%	1.59
P(t-Bu) ₃ -Pd-G4	568.08	0.02	0.114	10.0%	1.14
JackieiPhos/CPhos hybrid (7)	786.64	0.02	0.157	10.0%	1.57
JackieiPhos/RuPhos hybrid (8)	756.62	0.02	0.151	10.0%	1.51
t-BuBrettPhos-Pd-G3	856.54	0.02	0.171	10.0%	1.71
EPhos-Pd-G4	919.67	0.02	0.184	10.0%	1.84
BrettPhos-Pd-G4	906.60	0.02	0.181	10.0%	1.81
t-BuOK	112.23	2.0	2.24	n/a	n/a
KHMDS	199.53	2.0	3.99	n/a	n/a
Cs ₂ CO ₃	325.83	2.0	6.52	n/a	n/a
P2-Et	339.48	2.0	6.79	n/a	n/a

Figure S18: The plate design and the target dose for each component for the Buchwald-Hartwig secondary amine and aniline screening plate. [‡]Dosed as stock solution in THF.

Buchwald amide and oxygen screening kit

The plate design for the amide, oxygen and CN Buchwald screening plate can be seen below. An Analytical Sales 96 well Para-dox® Aluminium Reaction Block was dosed with all solid inorganic bases using the Chronect Quantos (Axel Semrau, Germany). The addition of the coupling partners follows the procedure listed below.




Reagent	FW (gmol ⁻¹)	Loading (equiv)	Mass (mg)	ChemBead loading	Mass (mg)
DMPDAB-Pd-MAH	468.84	0.02	0.094	10.0%	0.94
t-BuBrettPhos-Pd-G3	856.54	0.02	0.171	10.0%	1.71
4Met-BuXPhos-Pd-G3	850.58	0.02	0.170	10.0%	1.70
AdBrettPhos-Pd-G3	1010.76	0.02	0.202	10.0%	2.02
BINAP-Pd-G4	1006.43	0.02	0.201	10.0%	2.01
JackieiPhos-Pd-G3	1166.48	0.02	0.233	10.0%	2.33
t-BuXPhos-Pd-G3	794.46	0.02	0.159	10.0%	1.59
Me ₃ (OMe)t-BuXPhos-Pd-G3	822.52	0.02	0.165	10.0%	1.65
XPhos-Pd-G4	859.56	0.02	0.172	10.0%	1.72
BrettPhos-Pd-G3	920.63	0.02	0.184	10.0%	1.84
XantPhos-Pd-G4	962.43	0.02	0.192	10.0%	1.92
DPPF-Pd-G4	925.17	0.02	0.185	7.5%	2.47
RockPhos-Pd-G3	838.52	0.02	0.168	10.0%	1.68
JosiPhos-Pd-G3	926.4	0.02	0.185	10.0%	1.85
TrixiePhos-Pd-G3	768.31	0.02	0.154	10.0%	1.54
t-BuMePhos	312.47	0.02	0.062	5.0%	1.25
[BippyPhos-Pd(η^3 -allyl)]OTf	803.19	0.02	0.161	10.0%	1.61
Cs ₂ CO ₃	325.83	2.0	6.52	n/a	n/a
K ₃ PO ₄	212.27	2.0	4.25	n/a	n/a
KOAc	98.15	2.0	1.96	n/a	n/a

Figure S19: The plate design and the target dose for each component for the Buchwald-Hartwig amide and oxygen screening plate.

S_NAr screening kit

The plate design for the S_NAr screening plate can be seen below. An Analytical Sales 96 well Para-dox® Aluminium Reaction Block was dosed with all solid inorganic bases using the Chronect Quantos (Axel Semrau, Germany). The organic bases were added as neat solutions using the procedure listed below and the addition of the coupling partners follows the procedure listed below.



Reagent	FW (g mol ⁻¹)	Loading (equiv)	Mass (mg)
NEt ₃	101.22	4	4.05
DBU	152.27	4	6.09
TMG	115.21	4	4.61
DIPEA	129.28	4	5.17
Cs ₂ CO ₃	325.83	4	13.03
KHMDS	199.53	4	7.98
K ₃ PO ₄	212.27	4	8.49
t-BuOK	112.23	4	4.49
CsF	151.91	0.4	0.61


Figure S20: The plate design and the target dose for each component for the S_NAr screening plate.

Setting up the screening kits

The total amount of solid reagent was aliquoted into the number of solvents required for the screening plate and weighed into an appropriate vial (7 mL screw cap for Suzuki and S_NAr and 10-20 mL vial Biotage, 354833 for Buchwald-Hartwig), both coupling partners were added to the same vial and the vial was degassed if necessary. The appropriate solvent was then added, and the mixture was sonicated until all solid had dissolved. Liquid handling of reagents and stock solutions was performed by Andrew+ liquid handler (Andrew Alliance, Switzerland) equipped with Sartorius Picus® electronic pipettes or by hand using Sartorius Picus® electronic pipettes. If liquid reagents are required then these were added first, followed by the addition of the stock solutions. The plate was then sealed according to the manufacturers sealing guide and heated to an appropriate temperature overnight.

Creation of the analytical plates for MISER

Analytical plates with a 1-400-fold dilution were created using the Integra Mini 96 and the Viaflo 96 / 384. t-AmOH (95 µL) was added into all the coloured wells (figure S18) using the Integra Mini 96. Crude reaction mixture (5 µL) was added into wells coloured in light blue (figure S18), mixed five times, then an aliquot (5 µL) of the light blue well was transferred into the dark blue wells and mixed five times. The plate was sealed with a Thermo Scientific™ Easy Pierce Heat Sealing Foil (AB-1720).



Integra Mini 96



Integra Viaflo 96 / 384

Figure S21: The Integra liquid handlers (Mini 96 and Viaflo 96 / 384) utilised in the production of the analytical plates.





Figure S22: The plate layout for the 1-400-fold dilution required in the preparation of the screening plate.

Screening kit analysis – MISER analysis

Suzuki-Miyaura Cross-coupling screening plate; 5-bromo-1H-pyrrolo[2,3-b]pyridine and (2-fluorophenyl)boronic acid



MISER Analysis: 5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine (Desired Product)


Max response: 464370.25

m/z: 213

	1	2	3	4	5	6	7	8	9	10	11	12	Legend
A	1.81	39.06	54.70	6.32	44.10	10.05	5.98	91.10	44.49	5.51	76.17	17.29	66.7% ≤ val < 100.0%
B	6.56	16.40	25.86	1.76	5.59	13.91	19.20	8.84	68.14	15.26	19.90	1.60	33.3% ≤ val < 66.7%
C	4.69	24.15	27.73	0.77	24.56	10.52	2.89	10.74	48.30	58.30	67.42	9.04	0.0% ≤ val < 33.3%
D	8.09	7.72	50.41	7.94	8.02	26.70	3.40	15.37	66.73	6.03	15.83	45.28	
E	2.67	22.47	48.89	7.64	78.95	9.13	13.12	16.97	22.44	26.57	100.00	40.04	
F	15.70	7.80	47.67	5.21	11.37	24.74	26.35	9.13	62.82	36.25	44.81	39.78	
G	2.86	13.13	6.91	1.34	11.32	5.14	3.17	29.69	5.69	5.54	40.67	8.47	
H	21.08	12.99	5.85	1.56	7.08	30.28	7.74	30.93	2.48	3.88	22.58	19.10	

Well	MISER result (%)	LCAP (%)	LCMS spectra	
E11	100.00	80.0		
A8	91.10	70.0		
E5	78.95	76.0		

Buchwald primary amine screening plate (unhindered primary amine); 5-bromo-1H-pyrrolo[2,3-b]pyridine and 1-(pyridin-4-yl)methanamine



MISER Analysis: N-[(pyridin-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-amine (Desired Product)

Max response: 393248.44


m/z: 225

	1	2	3	4	5	6	7	8	9	10	11	12
A	0.00	0.00	0.50	3.63	0.57	10.53	5.35	0.00	0.00	68.87	2.54	14.94
B	47.00	100.00	0.00	2.40	0.59	56.23	42.03	22.66	6.38	0.37	0.00	16.56
C	8.69	1.30	0.36	58.03	0.46	1.04	77.94	0.00	0.00	63.90	2.51	34.14
D	0.48	64.31	0.47	0.37	0.00	1.04	0.00	0.42	1.02	0.00	0.00	22.40
E	0.00	0.00	0.00	0.29	0.00	0.00	9.26	0.00	0.00	6.89	0.00	0.55
F	1.58	10.08	0.00	0.00	0.00	0.56	5.13	1.42	0.00	0.00	0.00	0.00
G	2.46	0.00	0.00	0.72	0.00	0.00	0.35	0.00	0.00	3.70	0.00	0.00
H	2.10	4.08	0.00	0.00	0.00	1.27	0.34	11.18	0.00	0.00	0.00	0.00

Legend
66.7% ≤ val <100.0%
33.3% ≤ val <66.7%
0.0% ≤ val <33.3%

Well	MISER result (%)	LCAP (%)	LCMS spectra
B2	100.00	68.7	
C7	77.94	40.4	
A10	68.87	41.3	

Buchwald primary amine screening plate (hindered primary amine); 5-bromoisoquinoline and 2-phenylpropan-2-amine






MISER Analysis: N-(2-phenylpropan-2-yl)quinolin-4-amine (Desired Product)

Max response: 988515.56

m/z: 263

	1	2	3	4	5	6	7	8	9	10	11	12	Legend
A	2.80	2.13	0.00	0.00	0.00	0.00	0.00	0.00	2.58	0.00	0.00	7.38	66.7% ≤ val < 100.0%
B	1.27	0.00	14.54	2.16	2.27	3.59	0.00	0.00	100.00	51.09	0.00	2.56	33.3% ≤ val < 66.7%
C	0.00	0.00	2.93	0.00	4.29	43.62	0.00	0.00	0.00	0.00	0.00	9.07	0.0% ≤ val < 33.3%
D	45.35	31.57	0.00	0.00	38.58	41.40	0.00	0.00	8.40	0.00	13.59	0.00	
E	3.69	1.22	0.00	0.00	0.00	6.42	13.36	0.00	3.07	0.00	0.00	21.42	
F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	14.12	3.30	0.00	1.47	
G	1.12	0.00	0.00	0.00	0.00	0.00	1.47	0.00	0.00	0.00	0.00	1.79	
H	0.00	0.00	1.62	0.00	0.00	0.00	0.00	0.00	1.36	0.00	0.00	3.66	

Well	MISER result desired product (%)	LCAP (%)	LCMS spectra
B9	100.00	49.4	
B10	51.09	34.6	
D1	45.35	22.7	

Buchwald secondary amine / aniline screening plate (secondary amine); 5-bromo-1H-pyrrolo[2,3-b]pyridine and tert-butyl piperazine-1-carboxylate

MISER Analysis: tert-butyl 4-{1H-pyrrolo[2,3-b]pyridin-5-yl}piperazine-1-carboxylate (Desired Product)


Max response: 375059.47

m/z: 303


	1	2	3	4	5	6	7	8	9	10	11	12
A	41.12	0.00	0.00	3.52	45.10	9.54	82.72	0.00	0.00	0.00	25.69	35.57
B	38.87	6.48	0.00	3.55	0.00	10.46	20.50	0.00	24.84	17.04	0.00	59.47
C	70.66	54.67	100.00	83.17	88.80	73.81	68.42	0.00	0.00	53.91	17.01	31.18
D	53.58	70.06	73.61	65.26	51.66	47.18	0.00	0.00	22.17	18.04	0.00	53.54
E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
G	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
H	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Legend


66.7% ≤ val <100.0%
33.3% ≤ val <66.7%
0.0% ≤ val <33.3%



Well	MISER result desired product (%)	LCAP (%)	LCMS spectra	0.25 mmol scale up LCAP (%)
C3	100.00	24.0	<p>Mass spectrum showing peaks at m/z 303 (base peak), 350, and 378. Peak parameters: Si=1.00, A=1030568, A%=47, H%=49 for m/z 303; Si=1.00, A=515999, A%=24, H%=21 for m/z 350; Si=1.00, A=186781, A%=9, H%=5 for m/z 378.</p>	26.0
C5	88.80	28.0	<p>Mass spectrum showing peaks at m/z 303 (base peak), 350, and 378. Peak parameters: Si=1.00, A=560790, A%=4, H%=6 for m/z 303; Si=1.00, A=5773185, A%=39, H%=43 for m/z 350; Si=1.00, A=186781, A%=9, H%=5 for m/z 378.</p>	60.0

C4	83.17	28.0		33.0
----	-------	------	--	------

Buchwald secondary amine / aniline screening plate (aniline); 5-bromo-1H-pyrrolo[2,3-b]pyridine and 5-methoxypyridin-2-amine



MISER Analysis: 5-methoxy-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-2-amine (Desired Product)



Max response: 328926.25


m/z: 241

	1	2	3	4	5	6	7	8	9	10	11	12
A	49.71	0.00	0.00	4.16	10.62	0.00	0.00	0.00	0.00	3.95	25.74	
B	22.86	0.00	0.00	75.29	0.00	100.00	4.31	0.00	0.00	81.60	0.00	44.81
C	0.00	0.00	0.00	23.89	0.00	0.00	0.00	0.00	0.00	84.74	0.00	33.48
D	0.00	0.00	0.00	18.23	0.00	0.00	0.00	0.00	0.00	4.22	0.00	0.00
E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.26	27.75
F	0.00	0.00	0.00	8.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.76
G	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
H	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00


Legend

- 66.7% ≤ val <100.0%
- 33.3% ≤ val <66.7%
- 0.0% ≤ val <33.3%

Well	MISER result desired product (%)	LCAP (%)	LCMS spectra									
B6	100.00	73.3			(7) 0.694 0.689.33	(12) 0.871 116.27						
C11	84.74	72.2			(6) 0.694 2042.64							



Buchwald amide and oxygen screening kit (amide); 1-bromo-4-methoxybenzene and pyridine-3-carboxamide






MISER Analysis: N-(4-methoxyphenyl)pyridine-3-carboxamide (Desired Product)

Max response: 1890096.00


m/z: 229

	1	2	3	4	5	6	7	8	9	10	11	12
A	48.33	27.09	2.26	11.11	12.91	0.00	6.35	60.16	13.41	3.99	18.08	0.00
B	0.80	1.54	0.00	0.00	0.00	0.00	21.42	29.27	2.24	0.00	0.00	0.00
C	6.20	22.39	1.66	0.00	0.00	0.00	100.00	76.43	8.12	0.00	0.00	0.00
D	0.00	0.00	0.00	23.96	53.43	1.27	0.00	0.00	0.00	76.86	61.11	6.00
E	0.00	0.00	0.00	2.74	1.32	0.00	0.00	0.56	0.00	0.00	0.00	0.00
F	1.29	1.58	1.08	1.17	1.48	0.00	30.31	16.39	0.00	14.54	7.38	1.64
G	4.64	1.77	0.00	0.65	0.00	0.00	1.53	48.00	3.28	5.18	2.05	0.00
H	0.00	0.00	0.00	1.61	2.04	0.00	0.00	0.62	0.00	0.00	2.72	0.97

Legend
 66.7% ≤ val <100.0%
 33.3% ≤ val <66.7%
 0.0% ≤ val <33.3%

Well	MISER result desired product (%)	LCAP (%)	LCMS spectra
C7	100.00	98.5	
D10	76.86	98.1	
C8	81.60	97.8	

Buchwald amide and oxygen screening kit (oxygen); 6-chloroquinoline and tert-butyl 3-hydroxyazetidine-1-carboxylate




MISER Analysis: tert-butyl 3-(quinolin-6-yloxy)azetidine-1-carboxylate (Desired Product)


Max response: 730117.75

m/z: 301

												Legend	
	1	2	3	4	5	6	7	8	9	10	11	12	
A	74.79	62.43	2.12	34.18	6.38	2.02	14.09	2.64	0.00	0.00	0.00	0.00	66.7% ≤ val <100.0%
B	91.17	1.90	0.00	0.00	0.00	0.00	13.95	1.92	0.00	0.00	0.00	0.00	33.3% ≤ val <66.7%
C	19.63	31.07	0.00	0.00	0.00	0.00	2.68	2.90	0.00	0.00	0.00	0.00	0.0% ≤ val <33.3%
D	1.45	0.00	0.00	1.85	65.13	0.00	0.00	0.00	0.00	0.00	13.16	1.98	
E	29.38	8.17	0.00	0.00	6.93	0.00	0.00	0.00	0.00	11.82	0.00	0.00	
F	31.84	3.96	0.00	8.81	0.00	0.00	3.10	0.00	0.00	44.99	0.00	0.00	
G	100.00	2.77	0.00	1.95	0.00	0.00	0.00	14.02	0.00	1.44	1.92	0.00	
H	5.27	0.00	0.00	3.40	49.59	0.00	0.00	0.00	0.00	0.00	18.69	0.00	



SNAr screening plate:



MISER Analysis: methyl 7-(benzyloxy)-1H-indazole-4-carboxylate (Desired Product)

Max response: 365728.12

m/z: 281

	1	2	3	4	5	6	7	8	9	10	11	12
A	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
C	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
D	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
F	59.54	3.93	0.00	0.00	0.00	1.38	0.00	5.63	100.00	0.00	0.00	0.00
G	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
H	1.94	1.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Legend
66.7% ≤ val <100.0%
33.3% ≤ val <66.7%
0.0% ≤ val <33.3%


MISER Analysis: 1H-INDAZOLE-4-CARBOXYLIC ACID, 7-FLUORO-, METHYL ESTER (BT301412,FRIDGE F) (Reactant)

Max response: 429213.84

m/z: 193

	1	2	3	4	5	6	7	8	9	10	11	12
A	100.00	15.56	11.85	7.28	73.52	46.35	48.12	26.24	74.50	27.72	90.52	48.05
B	8.13	11.65	7.10	5.73	34.54	25.16	5.27	5.72	24.94	7.01	35.35	41.44
C	7.21	1.80	5.44	6.64	51.14	19.78	6.08	4.58	10.91	3.72	32.31	6.17
D	50.69	21.84	25.80	6.78	34.01	29.41	23.00	38.42	47.48	26.08	34.54	34.17
E	33.77	42.28	3.02	4.09	6.22	7.57	47.25	25.87	42.39	67.12	0.00	6.04
F	0.00	4.65	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.31	1.28	0.00
G	50.40	54.16	1.40	5.03	5.56	0.00	70.33	41.70	66.47	42.58	4.56	2.03
H	0.00	2.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00


Legend
0.0% ≤ val <33.3%
33.3% ≤ val <66.7%
66.7% ≤ val <100.0%



The peak with a retention time of 1.17 min represents the trans esterified product (*m/z* 359.4), where the desired product has reacted with excess benzyl alcohol to give the benzylated ester.

Batch scale-up reactions and characterization data

5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine (3)



Conditions identified on the plate: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), (2-fluorophenyl)boronic acid (52.5 mg, 0.38 mmol), APPhos-Pd-G3 (3.90 mg, 0.005 mmol, 2 mol%) and CsF (76.0 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar. t-AmOH:water (4:1, 2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 86%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a yellow solid (47.2 mg, 89% yield).

Closest literature conditions¹: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), (2-fluorophenyl)boronic acid (52.5 mg, 0.38 mmol), Pd(dppf)Cl₂ (3.66 mg, 0.005 mmol, 2 mol%) and K₂CO₃ (69.2 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar. Dioxane–water (4:1, 2.50 mL, 0.1 M) was added to the vial, which was then heated to 120 °C for 12 h. Crude reaction LCAP for desired product = 10%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a cream solid (3.0 mg, 6% yield).


¹H NMR (400 MHz, DMSO-*d*₆) δ 11.77 (s, 1H), 8.37 (d, *J* = 2.1 Hz, 1H), 8.11 (dd, *J* = 2.2, 0.8 Hz, 1H), 7.59 (dd, *J* = 7.6, 1.9 Hz, 1H), 7.53 (dd, *J* = 3.5, 2.5 Hz, 1H), 7.42 (ddd, *J* = 8.6, 7.0, 1.8 Hz, 1H), 7.32 (ddd, *J* = 8.7, 7.3, 1.4 Hz, 2H), 6.52 (dd, *J* = 3.5, 1.8 Hz, 1H).

¹³C NMR (101 MHz, DMSO-*d*₆) δ 159.2 (d, *J* = 245.0 Hz), 147.9, 142.7 (d, *J* = 3.3 Hz), 131.2 (d, *J* = 3.3 Hz), 129.2 (d, *J* = 8.2 Hz), 128.2 (d, *J* = 2.8 Hz), 127.0, 126.9 (d, *J* = 13.7 Hz), 125.0 (d, *J* = 3.4 Hz), 122.8, 119.9, 116.0 (d, *J* = 22.7 Hz), 100.2.

¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -118.66.

HRMS (ESI-QTOF): *m/z* [M+H]⁺ Calcd for C₁₃H₉FN₂ 213.0822; Found 213.0827. Δ = 2.24 ppm

N-[(pyridin-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-amine (4)



Conditions identified on the plate: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), 4-picollylamine (25.4 μ L, 0.38 mmol), AdBrettPhos-Pd-G3 (5.06 mg, 0.005 mmol, 2 mol%) and t-BuOK (56.2 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N_2 sparging (5–10 mins). Anhydrous dioxane (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 92%. The crude material was purified (11g KPNH Sfar cartridge, 0–100% EtOAc/Petrol v/v then 0–20% MeOH/EtOAc v/v) to afford the title compound as a pale-yellow oil (51.7 mg, 92% yield).


Closest literature conditions²: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), tert-butyl piperazine-1-carboxylate (69.9 mg, 0.38 mmol) and BrettPhos-Pd-G3 (2.27 mg, 0.005 mmol, 2 mol%) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N_2 sparging (5–10 mins). Anhydrous THF (2.0 mL, 0.1 M) and LiHMDS (1 M in THF, 0.5 mL, 0.50 mmol) were added to the vial, which was then heated to 80 °C for 16 h. LCMS indicated that no reaction had taken place, therefore no more was done with this sample.

1H NMR (400 MHz, DMSO- d_6) δ 11.13 (s, 1H), 8.53 – 8.46 (m, 2H), 7.81 (d, J = 2.6 Hz, 1H), 7.42 – 7.36 (m, 2H), 7.24 (t, J = 2.9 Hz, 1H), 6.98 – 6.92 (m, 1H), 6.15 (dd, J = 3.3, 1.9 Hz, 1H), 6.06 (t, J = 6.3 Hz, 1H), 4.35 (d, J = 6.2 Hz, 2H).

^{13}C NMR (101 MHz, DMSO- d_6) δ 149.8, 149.5, 142.7, 138.9, 132.3, 125.6, 122.4, 119.6, 108.9, 98.5, 46.3.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₃H₁₂N₄ 225.1135; Found 225.1143. Δ = 3.65 ppm

N-(2-phenylpropan-2-yl)isoquinolin-5-amine (5)



Conditions identified on the plate: 5-bromoisoquinoline (52.0 mg, 0.25 mmol), cumylamine (50.7 mg, 0.38 mmol), ^tBuPhCPhos-Pd-G4 (3.94 mg, 0.005 mmol, 2 mol%) and t-BuOK (56.2 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous t-AmOH (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 76%. The crude material was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v then 0–20% MeOH/EtOAc v/v) to afford the title compound as a pale-yellow oil (27.1 mg, 41.3% yield).


Closest literature conditions³: 5-bromoisoquinoline (52.0 mg, 0.25 mmol), cumylamine (50.7 mg, 0.38 mmol), ^tBuPhCPhos-Pd-G4 (3.94 mg, 0.005 mmol, 2 mol%) and t-BuOK (56.2 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous dioxane (2.0 mL, 0.1 M) were added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 7%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v then 0–20% MeOH/EtOAc v/v) but no material was successfully isolated.

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.09 (d, *J* = 0.9 Hz, 1H), 8.43 (d, *J* = 6.0 Hz, 1H), 8.27 (d, *J* = 6.0 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.31 (dd, *J* = 8.4, 7.0 Hz, 2H), 7.19 (ddt, *J* = 15.1, 8.6, 1.1 Hz, 2H), 7.11 (t, *J* = 7.9 Hz, 1H), 6.31 (s, 1H), 6.07 (dd, *J* = 7.7, 1.1 Hz, 1H), 1.72 (s, 6H).

¹³C NMR (101 MHz, DMSO-*d*₆) δ 152.0, 147.1, 141.0, 140.4, 129.2, 128.5, 127.4, 126.4, 126.2, 125.2, 115.4, 114.3, 110.7, 55.7, 29.8.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₈H₁₈N₂ 263.1543; Found 263.1549. Δ = 2.43 ppm

***tert*-Butyl 4-{1*H*-pyrrolo[2,3-*b*]pyridin-5-yl}piperazine-1-carboxylate (**9**)**



Conditions identified on the plate: 5-bromo-1*H*-pyrrolo[2,3-*b*]pyridine (49.3 mg, 0.25 mmol), *tert*-butyl piperazine-1-carboxylate (69.9 mg, 0.38 mmol), [BippyPhos Pd(allyl)]OTf (4.02 mg, 0.005 mmol, 2 mol%) and KHMDS (99.8 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous dioxane (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 60%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a colourless solid (46.3 mg, 61% yield).


Closest literature conditions²: 5-bromo-1*H*-pyrrolo[2,3-*b*]pyridine (49.3 mg, 0.25 mmol), *tert*-butyl piperazine-1-carboxylate (69.9 mg, 0.38 mmol) and RuPhos-Pd-G4 (4.54 mg, 0.005 mmol, 2 mol%) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous THF (2.0 mL, 0.1 M) and LiHMDS (1 M in THF, 0.5 mL, 0.50 mmol) were added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 37%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a colourless solid (31.0 mg, 41% yield).

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.38 (s, 1H), 8.07 (d, *J* = 2.6 Hz, 1H), 7.52 (dd, *J* = 2.7, 0.7 Hz, 1H), 7.38 (dd, *J* = 3.4, 2.5 Hz, 1H), 6.33 (dd, *J* = 3.4, 1.9 Hz, 1H), 3.50 (t, *J* = 5.1 Hz, 4H), 3.06 – 2.99 (m, 4H), 1.44 (s, 9H).

¹³C NMR (101 MHz, DMSO-*d*₆) δ 154.3, 144.8, 142.6, 137.0, 126.8, 119.9, 116.4, 99.8, 79.4, 51.6, 28.6.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₆H₂₂N₄O₂ 303.1812; Found 303.182. Δ = 2.65 ppm

5-methoxy-N-[1H-pyrrolo[2,3-b]pyridin-5-yl]pyridin-2-amine (10)



Conditions identified on the plate: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), 5-methoxypyridin-2-amine (46.6 mg, 0.38 mmol), BrettPhos-Pd-G4 (4.54 mg, 0.005 mmol, 2 mol%) and t-BuOK (56.2 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous dioxane (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 76%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a beige solid (52.0 mg, 86% yield).


Closest literature conditions²: 5-bromo-1H-pyrrolo[2,3-b]pyridine (49.3 mg, 0.25 mmol), 5-methoxypyridin-2-amine (46.6 mg, 0.38 mmol) and BrettPhos-Pd-G3 (4.54 mg, 0.005 mmol, 2 mol%) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous dioxane (2.50 mL, 0.1 M) and LiHMDS (1 M in THF, 0.5 mL, 0.50 mmol) were added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 46%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a beige solid (30.2 mg, 50% yield).

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.35 (s, 1H), 8.62 (s, 1H), 8.32 (dd, *J* = 2.4, 0.7 Hz, 1H), 8.25 (d, *J* = 2.4 Hz, 1H), 7.87 (dd, *J* = 3.1, 0.7 Hz, 1H), 7.37 (dd, *J* = 3.4, 2.5 Hz, 1H), 7.28 (dd, *J* = 9.0, 3.1 Hz, 1H), 6.78 (dd, *J* = 9.0, 0.7 Hz, 1H), 6.36 (dd, *J* = 3.4, 1.9 Hz, 1H), 3.75 (s, 3H).

¹³C NMR (101 MHz, DMSO-*d*₆) δ 151.4, 148.8, 144.2, 136.1, 132.3, 132.2, 126.2, 125.4, 119.3, 117.1, 110.6, 99.4, 56.0.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₃H₁₂N₄O 241.1085; Found 241.1086. Δ = 0.24 ppm.

N-(4-methoxyphenyl)pyridine-3-carboxamide (11)



Conditions identified on the plate: 1-bromo-4-methoxybenzene (46.8 mg, 0.25 mmol), nitcotinamide (45.8 mg, 0.38 mmol), AdBrettPhos-Pd-G3 (5.06 mg, 0.005 mmol, 2 mol%) and Cs₂CO₃ (163.0 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous t-AmOH (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 92%. The crude material was dissolved in the minimum amount of EtOAc and a precipitate formed, which was collected under vacuum, washed with EtOAc, giving the title compound⁵ as a cream solid (49.8 mg, 87% yield).

Exact literature conditions ⁴: 1-bromo-4-methoxybenzene (46.8 mg, 0.25 mmol), nitcotinamide (45.8 mg, 0.38 mmol), ^tBuBrettPhos-Pd-G3 (5.06 mg, 0.005 mmol, 2 mol%) and K₃PO₄ (74.4 mg, 0.35 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). t-BuOH (0.5 mL, 0.5 M) was added to the vial, which was then heated to 110 °C for 6 h. Crude reaction LCAP for desired product = 86%. The crude material was dissolved in the minimum amount of EtOAc and a precipitate formed, which was collected under vacuum, washed with EtOAc, giving the title compound⁵ as a cream solid (47.1 mg, 82% yield).


Characterization data matches the literature⁴

¹H NMR (400 MHz, MeOD) δ 9.07 (dd, *J* = 2.3, 0.9 Hz, 1H), 8.71 (dd, *J* = 4.9, 1.6 Hz, 1H), 8.34 (ddd, *J* = 8.0, 2.3, 1.6 Hz, 1H), 7.63 – 7.54 (m, 3H), 6.98 – 6.90 (m, 2H), 3.81 (s, 3H).

¹³C NMR (101 MHz, MeOD) δ 166.2, 158.5, 152.7, 149.3, 137.2, 132.8, 132.4, 125.1, 124.0, 115.0, 55.9.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₃H₁₂N₂O₂ 229.0971; Found 229.0975. Δ = 1.66 ppm

tert-butyl 3-(quinolin-6-yloxy)azetidine-1-carboxylate (12)



Conditions identified on the plate: 6-Chloroquinoline (40.9 mg, 0.25 mmol), 1-Boc-3-(hydroxy)azetidine (65.0 mg, 0.38 mmol), Me₃(OMe)^tBuXPhos Pd G3 (4.11 mg, 0.005 mmol, 2 mol%) and Cs₂CO₃ (163.0 mg, 0.50 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar which was degassed by N₂ sparging (5–10 mins). Anhydrous toluene (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Crude reaction LCAP for desired product = 89%. The crude product was purified by achiral SFC (20:80 MeOH:CO₂; 60mL/min) to afford the title compound as a sticky pale-yellow oil (63.0 mg, 84% yield).

Exact literature conditions⁵: The literature method uses AdCyBrettPhos-Pd-G3, which is not commercially available and thus would need to be synthesised, this is prohibitive, so this method cannot be repeated.


Characterization data matches the literature⁵

¹H NMR (400 MHz, MeOD) δ 8.70 (dd, J = 4.4, 1.7 Hz, 1H), 8.27 (ddd, J = 8.2, 1.7, 0.8 Hz, 1H), 8.00 – 7.93 (m, 1H), 7.47 (ddd, J = 20.5, 8.8, 3.5 Hz, 2H), 7.09 (d, J = 2.8 Hz, 1H), 5.14 (tt, J = 6.4, 3.9 Hz, 1H), 4.49 – 4.40 (m, 2H), 3.99 (dd, J = 10.4, 3.6 Hz, 2H), 1.46 (s, 9H).

¹³C NMR (101 MHz, MeOD) δ 158.1, 156.4, 149.1, 145.1, 137.3, 131.0, 130.9, 123.9, 122.9, 107.9, 81.4, 67.5, 28.6.

HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₇H₂₀N₂O₃ 301.1547; Found 301.1551. Δ = 1.45 ppm

methyl 7-(benzyloxy)-1H-indazole-4-carboxylate (15)



Conditions identified on the plate: Methyl 7-fluoro-1H-indazole-4-carboxylate (48.5 mg, 0.25 mmol), benzyl alcohol (40.5 mg, 0.38 mmol), KHMDS (199.0 mg, 0.5 mmol) and CsF (15.2 mg, 0.01 mmol) were weighed into a crimp top glass vial (2–5 mL vial Biotage, 354833) equipped with a magnetic stir bar. NMP (2.50 mL, 0.1 M) was added to the vial, which was then heated to 80 °C for 16 h. Again, in the LCMS of the crude reaction the trans esterified product was observed therefore MeOH (1 mL) was added, and the reaction was heated to 60 °C for 3 h. Crude reaction LCAP for desired product = 61%. The crude product was purified (10g Sfar cartridge, 0–100% EtOAc/Petrol v/v) to afford the title compound as a colourless oil (59.9 mg, 85% yield).

Closest literature conditions: There are no exact or similar reactions on SciFinderⁿ for this heterocycle.

¹H NMR (400 MHz, DMSO-*d*₆) δ 13.74 – 13.69 (m, 1H), 8.37 – 8.33 (m, 1H), 7.80 (d, *J* = 8.0 Hz, 1H), 7.62 – 7.55 (m, 2H), 7.48 – 7.32 (m, 3H), 7.06 (d, *J* = 8.1 Hz, 1H), 5.41 (s, 2H), 3.89 (s, 3H).

¹³C NMR (101 MHz, DMSO-*d*₆) δ 165.9, 148.4, 136.2, 134.1, 132.1, 128.5, 128.1, 127.8, 126.3, 122.9, 114.0, 105.6, 69.9, 51.7.



HRMS (ESI-QTOF): m/z [M+H]⁺ Calcd for C₁₆H₁₄N₂O₃ 283.1076; Found 283.1079. Δ = 0.93 ppm

Experimental References


1. Kaneko, Takushi; et al. World Intellectual Property Organization, WO2021062316 A1 2021-04-01
2. Henderson, J. L. McDermott, S. M. Buchwald, S. L. *Org. Lett.*, **12**, 4438-4441 (2010).
3. Ruiz-Castillo, P. Blackmond, D. G. Buchwald, S. L. *J. Am. Chem. Soc.*, **137**, 3085-3092 (2015).
4. Fors, B. P. Dooleweerd, K. Zeng, Q. Buchwald, S. L. *Tetrahedron*, **65**, 6576–6583 (2009).
5. Zhang, H. Ruiz-Castillo, P. Schuppe, A. W., Buchwald, S. L. *Org. Lett.*, **22**, 14, 5369–5374 (2020).

NMR spectra


5-(2-fluorophenyl)-1H-pyrrolo[2,3-b]pyridine (3)





¹⁹F





N-[(pyridin-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-amine (4)





***N*-(2-phenylpropan-2-yl)isoquinolin-5-amine (5)**




tert-Butyl 4-{1H-pyrrolo[2,3-b]pyridin-5-yl}piperazine-1-carboxylate (9)





5-methoxy-N-{1H-pyrrolo[2,3-b]pyridin-5-yl}pyridin-2-amine (10)





N-(4-methoxyphenyl)pyridine-3-carboxamide (11)⁴



***tert*-butyl 3-(quinolin-6-yloxy)azetidine-1-carboxylate (12)⁵**



methyl 7-(benzyloxy)-1H-indazole-4-carboxylate



Tabulated MISER data:
Suzuki-Miyaura screening kit

Cell ID	Desired Product (%)	Reactant (%)	Components
E11	100.00	9.84	APhos-Pd-G3: 0.13 mg CsF: 3.04 mg t-AmOH: 80.00 uL H2O: 20.00 uL
A8	91.10	23.10	DTBPF-Pd-G3: 0.17 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
E5	78.95	9.23	APhos-Pd-G3: 0.13 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
A11	76.17	5.08	APhos-Pd-G3: 0.13 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
B9	68.14	11.65	PCy3-Pd-G4: 0.13 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
C11	67.42	17.60	APhos-Pd-G3: 0.13 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
D9	66.73	20.29	PCy3-Pd-G4: 0.13 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
F9	62.82	15.12	PCy3-Pd-G4: 0.13 mg CsF: 3.04 mg t-AmOH: 80.00 uL H2O: 20.00 uL
C10	58.30	100.00	XPhos-Pd-G3: 0.17 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
A3	54.70	8.36	cataCXium A-Pd-G3: 0.15 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
D3	50.41	18.28	PCy3-Pd-G4: 0.13 mg K3PO4: 4.25 mg dioxane: 80.00 uL H2O: 20.00 uL
E3	48.89	50.28	cataCXium A-Pd-G3: 0.15 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
C9	48.30	28.66	cataCXium A-Pd-G3: 0.15 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
F3	47.67	12.69	PCy3-Pd-G4: 0.13 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
D12	45.28	31.62	IPr(h3-indenyl)PdCl: 0.14 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL

F11	44.81	28.59	Pd(dppf)Cl ₂ : 0.13 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
A9	44.49	0.00	cataCXium A-Pd-G3: 0.15 mg K ₂ CO ₃ : 2.76 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
A5	44.10	27.51	APhos-Pd-G3: 0.13 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
G11	40.67	17.83	APhos-Pd-G3: 0.13 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
E12	40.04	26.33	RuPhos-Pd-G4: 0.17 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
F12	39.78	30.50	IPr(h ₃ -indenyl)PdCl: 0.14 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
A2	39.06	7.54	DTBPF-Pd-G3: 0.17 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
F10	36.25	18.51	DavePhos-Pd-G3: 0.15 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
H8	30.93	35.02	P(t-Bu) ₃ -Pd-G4: 0.11 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
H6	30.28	27.37	IPr(h ₃ -indenyl)PdCl: 0.14 mg NaOH: 0.80 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
G8	29.69	38.02	DTBPF-Pd-G3: 0.17 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
C3	27.73	61.67	cataCXium A-Pd-G3: 0.15 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
D6	26.70	0.00	IPr(h ₃ -indenyl)PdCl: 0.14 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
E10	26.57	31.48	XPhos-Pd-G3: 0.17 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
F7	26.35	32.54	BrettPhos-Pd-G3: 0.18 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
B3	25.86	9.86	PCy ₃ -Pd-G4: 0.13 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
F6	24.74	9.48	IPr(h ₃ -indenyl)PdCl: 0.14 mg CsF: 3.04 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
C5	24.56	8.35	APhos-Pd-G3: 0.13 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
C2	24.15	58.05	DTBPF-Pd-G3: 0.17 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
H11	22.58	53.75	Pd(dppf)Cl ₂ : 0.13 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
E2	22.47	0.00	DTBPF-Pd-G3: 0.17 mg CsF: 3.04 mg dioxane:

			80.00 uL H2O: 20.00 uL
E9	22.44	0.00	cataCXium A-Pd-G3: 0.15 mg CsF: 3.04 mg t-AmOH: 80.00 uL H2O: 20.00 uL
H1	21.08	50.65	BrettPhos-Pd-G3: 0.18 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
B11	19.90	44.60	Pd(dppf)Cl2: 0.13 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
B7	19.20	53.62	BrettPhos-Pd-G3: 0.18 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
H12	19.10	48.89	IPr(h3-indenyl)PdCl: 0.14 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H2O: 20.00 uL
A12	17.29	52.22	RuPhos-Pd-G4: 0.17 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
E8	16.97	0.00	DTBPF-Pd-G3: 0.17 mg CsF: 3.04 mg t-AmOH: 80.00 uL H2O: 20.00 uL
B2	16.40	38.03	P(t-Bu)3-Pd-G4: 0.11 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
D11	15.83	33.94	Pd(dppf)Cl2: 0.13 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
F1	15.70	55.43	BrettPhos-Pd-G3: 0.18 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
D8	15.37	7.19	P(t-Bu)3-Pd-G4: 0.11 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
B10	15.26	56.55	DavePhos-Pd-G3: 0.15 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
B6	13.91	49.46	IPr(h3-indenyl)PdCl: 0.14 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
G2	13.13	14.96	DTBPF-Pd-G3: 0.17 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
E7	13.12	12.13	SPhos-Pd-G3: 0.16 mg CsF: 3.04 mg t-AmOH: 80.00 uL H2O: 20.00 uL
H2	12.99	33.61	P(t-Bu)3-Pd-G4: 0.11 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
F5	11.37	46.61	Pd(dppf)Cl2: 0.13 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
G5	11.32	11.57	APhos-Pd-G3: 0.13 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
C8	10.74	0.00	DTBPF-Pd-G3: 0.17 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
C6	10.52	33.38	RuPhos-Pd-G4: 0.17 mg K3PO4: 4.25 mg dioxane: 80.00 uL H2O: 20.00 uL

A6	10.05	58.15	RuPhos-Pd-G4: 0.17 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
F8	9.13	5.27	P(t-Bu) ₃ -Pd-G4: 0.11 mg CsF: 3.04 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
E6	9.13	0.00	RuPhos-Pd-G4: 0.17 mg CsF: 3.04 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
C12	9.04	32.99	RuPhos-Pd-G4: 0.17 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
B8	8.84	5.77	P(t-Bu) ₃ -Pd-G4: 0.11 mg K ₂ CO ₃ : 2.76 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
G12	8.47	35.19	RuPhos-Pd-G4: 0.17 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
D1	8.09	54.89	BrettPhos-Pd-G3: 0.18 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
D5	8.02	33.17	Pd(dppf)Cl ₂ : 0.13 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
D4	7.94	38.07	DavePhos-Pd-G3: 0.15 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
F2	7.80	31.24	P(t-Bu) ₃ -Pd-G4: 0.11 mg CsF: 3.04 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
H7	7.74	36.12	BrettPhos-Pd-G3: 0.18 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
D2	7.72	22.20	P(t-Bu) ₃ -Pd-G4: 0.11 mg K ₃ PO ₄ : 4.25 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
E4	7.64	0.00	XPhos-Pd-G3: 0.17 mg CsF: 3.04 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
H5	7.08	52.56	Pd(dppf)Cl ₂ : 0.13 mg NaOH: 0.80 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
G3	6.91	44.73	cataCXium A-Pd-G3: 0.15 mg NaOH: 0.80 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
B1	6.56	37.84	BrettPhos-Pd-G3: 0.18 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
A4	6.32	54.62	XPhos-Pd-G3: 0.17 mg K ₂ CO ₃ : 2.76 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
D10	6.03	19.06	DavePhos-Pd-G3: 0.15 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
A7	5.98	54.77	SPhos-Pd-G3: 0.16 mg K ₂ CO ₃ : 2.76 mg t-AmOH: 80.00 uL H ₂ O: 20.00 uL
H3	5.85	8.93	PCy ₃ -Pd-G4: 0.13 mg NaOH: 0.80 mg dioxane: 80.00 uL H ₂ O: 20.00 uL
G9	5.69	13.52	cataCXium A-Pd-G3: 0.15 mg NaOH: 0.80

			mg t-AmOH: 80.00 uL H2O: 20.00 uL
B5	5.59	13.34	Pd(dppf)Cl2: 0.13 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
G10	5.54	40.36	XPhos-Pd-G3: 0.17 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H2O: 20.00 uL
A10	5.51	5.89	XPhos-Pd-G3: 0.17 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
F4	5.21	10.19	DavePhos-Pd-G3: 0.15 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
G6	5.14	35.56	RuPhos-Pd-G4: 0.17 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
C1	4.69	62.39	SPhos-Pd-G3: 0.16 mg K3PO4: 4.25 mg dioxane: 80.00 uL H2O: 20.00 uL
H10	3.88	10.10	DavePhos-Pd-G3: 0.15 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H2O: 20.00 uL
D7	3.40	5.18	BrettPhos-Pd-G3: 0.18 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
G7	3.17	32.14	SPhos-Pd-G3: 0.16 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H2O: 20.00 uL
C7	2.89	7.80	SPhos-Pd-G3: 0.16 mg K3PO4: 4.25 mg t-AmOH: 80.00 uL H2O: 20.00 uL
G1	2.86	57.22	SPhos-Pd-G3: 0.16 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
E1	2.67	0.00	SPhos-Pd-G3: 0.16 mg CsF: 3.04 mg dioxane: 80.00 uL H2O: 20.00 uL
H9	2.48	14.51	PCy3-Pd-G4: 0.13 mg NaOH: 0.80 mg t-AmOH: 80.00 uL H2O: 20.00 uL
A1	1.81	65.55	SPhos-Pd-G3: 0.16 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
B4	1.76	6.03	DavePhos-Pd-G3: 0.15 mg K2CO3: 2.76 mg dioxane: 80.00 uL H2O: 20.00 uL
B12	1.60	54.84	IPr(h3-indenyl)PdCl: 0.14 mg K2CO3: 2.76 mg t-AmOH: 80.00 uL H2O: 20.00 uL
H4	1.56	9.77	DavePhos-Pd-G3: 0.15 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
G4	1.34	8.34	XPhos-Pd-G3: 0.17 mg NaOH: 0.80 mg dioxane: 80.00 uL H2O: 20.00 uL
C4	0.77	6.03	XPhos-Pd-G3: 0.17 mg K3PO4: 4.25 mg dioxane: 80.00 uL H2O: 20.00 uL

Buchwald-Hartwig primary amine screening kit (primary amine)

Cell ID	Desired Product (%)	Reactant (%)	Components
			5-bromo-1H-pyrrolo[2,3-b]pyridin-5-amine
	N-[(pyridin-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-5-amine Max Resp:393248.4 <i>m/z</i> :225	Max Resp:46931.4 <i>m/z</i> :197	
B2	100.00	20.87	AdBrettPhos Pd G3: 0.20 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C7	77.94	0.00	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
A10	68.87	0.00	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D2	64.31	26.04	AdBrettPhos Pd G3: 0.20 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C10	63.90	0.00	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
C4	58.03	26.51	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
B6	56.23	27.63	Gphos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B1	47.00	52.02	Me3(OMe)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B7	42.03	16.42	Me3(OMe)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C12	34.14	16.89	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B8	22.66	0.00	AdBrettPhos Pd G3: 0.20 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D12	22.40	19.13	Gphos Pd G3: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B12	16.56	11.76	Gphos Pd G3: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A12	14.94	15.05	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
H8	11.18	12.15	P2-Et: 6.66 uL AdBrettPhos Pd G3: 0.20 mg t-AmOH: 100.00 uL

A6	10.53	34.24	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F2	10.08	35.30	Cs ₂ CO ₃ : 6.52 mg AdBrettPhos Pd G3: 0.20 mg dioxane: 100.00 uL
E7	9.26	29.65	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
C1	8.69	46.96	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg KHMDS: 3.99 mg dioxane: 100.00 uL
E10	6.89	21.10	Cs ₂ CO ₃ : 6.52 mg tBuBrettPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
B9	6.38	39.56	(tBu)PhCPhos Pd G4: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A7	5.35	0.00	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg T-BuOK: 2.24 mg t-AmOH: 100.00 uL
F7	5.13	18.45	Cs ₂ CO ₃ : 6.52 mg Me ₃ (OMe)tBuXPhos Pd G3: 0.16 mg t-AmOH: 100.00 uL
H2	4.08	0.00	P2-Et: 6.66 uL AdBrettPhos Pd G3: 0.20 mg dioxane: 100.00 uL
G10	3.70	4.34	P2-Et: 6.66 uL tBuBrettPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
A4	3.63	39.34	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A11	2.54	49.06	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C11	2.51	32.09	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
G1	2.46	34.70	P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg dioxane: 100.00 uL
B4	2.40	54.00	DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg T-BuOK: 2.24 mg dioxane: 100.00 uL
H1	2.10	11.09	P2-Et: 6.66 uL Me ₃ (OMe)tBuXPhos Pd G3: 0.16 mg dioxane: 100.00 uL
F1	1.58	36.01	Cs ₂ CO ₃ : 6.52 mg Me ₃ (OMe)tBuXPhos Pd G3: 0.16 mg dioxane: 100.00 uL
F8	1.42	41.61	Cs ₂ CO ₃ : 6.52 mg AdBrettPhos Pd G3: 0.20 mg t-AmOH: 100.00 uL
C2	1.30	50.36	MorDalPhos Pd G4: 0.17 mg KHMDS: 3.99

			mg dioxane: 100.00 uL
H6	1.27	11.67	P2-Et: 6.66 uL Gphos Pd G3: 0.18 mg dioxane: 100.00 uL
D6	1.04	55.97	Gphos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C6	1.04	46.33	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D9	1.02	36.14	(tBu)PhCPhos Pd G4: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
G4	0.72	6.91	P2-Et: 6.66 uL tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
B5	0.59	45.62	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A5	0.57	26.80	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F6	0.56	40.12	Cs ₂ CO ₃ : 6.52 mg Gphos Pd G3: 0.18 mg dioxane: 100.00 uL
E12	0.55	24.71	Cs ₂ CO ₃ : 6.52 mg [Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-AmOH: 100.00 uL
A3	0.50	41.66	JosiPhos Pd G3: 0.19 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
D1	0.48	5.38	Me ₃ (OMe)tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D3	0.47	50.44	(tBu)PhCPhos Pd G4: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C5	0.46	37.28	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D8	0.42	49.32	AdBrettPhos Pd G3: 0.20 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B10	0.37	29.76	DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D4	0.37	35.01	DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C3	0.36	14.20	JosiPhos Pd G3: 0.19 mg KHMDS: 3.99 mg dioxane: 100.00 uL
G7	0.35	7.40	P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg t-AmOH: 100.00 uL

H7	0.34	3.63	P2-Et: 6.66 uL Me3(OMe)tBuXPhos Pd G3: 0.16 mg t-AmOH: 100.00 uL
E4	0.29	50.90	tBuBrettPhos Pd G3: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
A1	0.00	100.00	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A2	0.00	14.78	MorDalPhos Pd G4: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A8	0.00	39.43	MorDalPhos Pd G4: 0.17 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A9	0.00	34.07	JosiPhos Pd G3: 0.19 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B3	0.00	0.00	(tBu)PhCPhos Pd G4: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B11	0.00	36.60	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C8	0.00	54.40	MorDalPhos Pd G4: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
C9	0.00	20.27	JosiPhos Pd G3: 0.19 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D5	0.00	41.27	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D7	0.00	41.11	Me3(OMe)tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D10	0.00	34.10	DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D11	0.00	32.60	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
E1	0.00	44.98	DMPDAB Pd MAH: 0.09 mg Ad-BippyPhos: 0.13 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E2	0.00	38.32	MorDalPhos Pd G4: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E3	0.00	46.12	JosiPhos Pd G3: 0.19 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E5	0.00	48.24	BrettPhos Pd G3: 0.18 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E6	0.00	35.60	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL

E8	0.00	41.10	Cs ₂ CO ₃ : 6.52 mg MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
E9	0.00	48.02	Cs ₂ CO ₃ : 6.52 mg JosiPhos Pd G3: 0.19 mg t-AmOH: 100.00 uL
E11	0.00	22.26	Cs ₂ CO ₃ : 6.52 mg BrettPhos Pd G3: 0.18 mg t-AmOH: 100.00 uL
F3	0.00	32.93	Cs ₂ CO ₃ : 6.52 mg (tBu)PhCPhos Pd G4: 0.16 mg dioxane: 100.00 uL
F4	0.00	49.77	Cs ₂ CO ₃ : 6.52 mg DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg dioxane: 100.00 uL
F5	0.00	39.18	Cs ₂ CO ₃ : 6.52 mg Pd PEPPSI Ipr: 0.14 mg dioxane: 100.00 uL
F9	0.00	37.26	Cs ₂ CO ₃ : 6.52 mg (tBu)PhCPhos Pd G4: 0.16 mg t-AmOH: 100.00 uL
F10	0.00	36.96	Cs ₂ CO ₃ : 6.52 mg DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg t-AmOH: 100.00 uL
F11	0.00	17.61	Cs ₂ CO ₃ : 6.52 mg Pd PEPPSI Ipr: 0.14 mg t-AmOH: 100.00 uL
F12	0.00	21.22	Cs ₂ CO ₃ : 6.52 mg Gphos Pd G3: 0.18 mg t- AmOH: 100.00 uL
G2	0.00	7.43	P2-Et: 6.66 uL MorDalPhos Pd G4: 0.17 mg dioxane: 100.00 uL
G3	0.00	8.45	P2-Et: 6.66 uL JosiPhos Pd G3: 0.19 mg dioxane: 100.00 uL
G5	0.00	7.49	P2-Et: 6.66 uL BrettPhos Pd G3: 0.18 mg dioxane: 100.00 uL
G6	0.00	8.10	P2-Et: 6.66 uL [Pd(bippyPhos)(allyl)]OTf: 0.16 mg dioxane: 100.00 uL
G8	0.00	15.96	P2-Et: 6.66 uL MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
G9	0.00	12.35	P2-Et: 6.66 uL JosiPhos Pd G3: 0.19 mg t- AmOH: 100.00 uL
G11	0.00	0.00	P2-Et: 6.66 uL BrettPhos Pd G3: 0.18 mg t-AmOH: 100.00 uL
G12	0.00	5.50	P2-Et: 6.66 uL [Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-AmOH: 100.00 uL
H3	0.00	7.36	P2-Et: 6.66 uL (tBu)PhCPhos Pd G4: 0.16 mg dioxane: 100.00 uL
H4	0.00	10.81	P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg dioxane: 100.00 uL
H5	0.00	3.46	P2-Et: 6.66 uL Pd PEPPSI Ipr: 0.14

			mg dioxane: 100.00 uL
H9	0.00	4.67	P2-Et: 6.66 uL (tBu)PhCPhos Pd G4: 0.16 mg t-AmOH: 100.00 uL
H10	0.00	9.61	P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg PhCPhos: 0.08 mg t-AmOH: 100.00 uL
H11	0.00	6.63	P2-Et: 6.66 uL Pd PEPPSI Ipr: 0.14 mg t- AmOH: 100.00 uL
H12	0.00	3.04	P2-Et: 6.66 uL Gphos Pd G3: 0.18 mg t- AmOH: 100.00 uL

Buchwald-Hartwig primary amine screening plate (sterically hindered primary amine)

Cell ID	Desired Product (%)			Components
		Reactant (%)	Reactant (%)	
	N-(2-phenylpropan-2-yl)quinolin-4-amine	CUMYLAMINE (BT107694, TOXIC C)	4-BROMOQUINOLINE (BT117687, B)	
	Max Resp:988515.6	Max Resp:0.0	Max Resp:605374.8	
	m/z:263	m/z:136	m/z:208	
D2	31.57	0.00	0.00	AdBrettPhos Pd G3: 0.20 mg KHMDS: 3.99 mg dioxane: 100.00 uL
B9	100.00	0.00	0.17	(tBu)PhCPhos Pd G4: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D5	38.58	0.00	0.17	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg dioxane: 100.00 uL
B4	2.16	0.00	0.17	PhCPhos: 0.08 mg t-BuOK: 2.24 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
H3	1.62	0.00	0.17	(tBu)PhCPhos Pd G4: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
E3	0.00	0.00	0.17	JosiPhos Pd G3: 0.19 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
B6	3.59	0.00	0.18	Gphos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane:

				100.00 uL
H9	1.36	0.00	0.18	(tBu)PhCPhos Pd G4: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H7	0.00	0.00	0.18	Me3(OMe)tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
E9	3.07	0.00	0.19	JosiPhos Pd G3: 0.19 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
H6	0.00	0.00	0.19	Gphos Pd G3: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G5	0.00	0.00	0.19	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
E2	1.22	0.00	0.21	Cs2CO3: 6.52 mg MorDalPhos Pd G4: 0.17 mg dioxane: 100.00 uL
B7	0.00	0.00	0.21	Me3(OMe)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A7	0.00	0.00	0.21	t-BuOK: 2.24 mg Ad-BippyPhos: 0.13 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
F11	0.00	0.00	0.22	Pd PEPPSI Ipr: 0.14 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
H4	0.00	0.00	0.23	PhCPhos: 0.08 mg P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
F5	0.00	0.00	0.23	Pd PEPPSI Ipr: 0.14 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
C5	4.29	0.00	0.26	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
H2	0.00	0.00	0.27	AdBrettPhos Pd G3: 0.20 mg P2-Et: 6.66 uL dioxane: 100.00 uL
F4	0.00	0.00	0.27	PhCPhos: 0.08 mg Cs2CO3: 6.52 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL

B3	14.54	0.00	0.28	(tBu)PhCPhos Pd G4: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C6	43.62	0.00	0.31	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
G12	1.79	0.00	0.31	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
F2	0.00	0.00	0.34	AdBrettPhos Pd G3: 0.20 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F9	14.12	0.00	0.37	(tBu)PhCPhos Pd G4: 0.16 mg Cs ₂ CO ₃ : 6.52 mg t- AmOH: 100.00 uL
G3	0.00	0.00	0.60	JosiPhos Pd G3: 0.19 mg P2- Et: 6.66 uL dioxane: 100.00 uL
G4	0.00	0.00	0.82	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL dioxane: 100.00 uL
C10	0.00	0.00	8.76	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
F10	3.30	0.00	9.36	PhCPhos: 0.08 mg Cs ₂ CO ₃ : 6.52 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
C8	0.00	0.00	9.76	KHMDS: 3.99 mg MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
D6	41.40	0.00	15.78	Gphos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
H5	0.00	0.00	17.00	Pd PEPPSI Ipr: 0.14 mg P2- Et: 6.66 uL dioxane: 100.00 uL
G11	0.00	0.00	18.60	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
C7	0.00	0.00	22.40	Ad-BippyPhos: 0.13 mg KHMDS: 3.99 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
F12	1.47	0.00	22.48	Gphos Pd G3: 0.18

				mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
H10	0.00	0.00	22.70	PhCPhos: 0.08 mg P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
E10	0.00	0.00	23.06	tBuBrettPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
G9	0.00	0.00	23.60	JosiPhos Pd G3: 0.19 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
D1	45.35	0.00	23.64	Me ₃ (OMe)tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D11	13.59	0.00	26.47	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B10	51.09	0.00	27.32	PhCPhos: 0.08 mg t-BuOK: 2.24 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
A9	2.58	0.00	28.92	JosiPhos Pd G3: 0.19 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A1	2.80	0.00	29.30	Ad-BippyPhos: 0.13 mg t-BuOK: 2.24 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
C11	0.00	0.00	30.17	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
E7	13.36	0.00	31.45	Ad-BippyPhos: 0.13 mg Cs ₂ CO ₃ : 6.52 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
G7	1.47	0.00	31.67	Ad-BippyPhos: 0.13 mg P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
A6	0.00	0.00	32.67	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B11	0.00	0.00	35.03	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL

G8	0.00	0.00	35.83	P2-Et: 6.66 uL MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
F7	0.00	0.00	36.48	Me3(OMe)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg t- AmOH: 100.00 uL
H8	0.00	0.00	37.87	AdBrettPhos Pd G3: 0.20 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
A3	0.00	0.00	37.98	JosiPhos Pd G3: 0.19 mg t- BuOK: 2.24 mg dioxane: 100.00 uL
D8	0.00	0.00	38.22	AdBrettPhos Pd G3: 0.20 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
E12	21.42	0.00	38.44	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs2CO3: 6.52 mg t- AmOH: 100.00 uL
D7	0.00	0.00	39.34	Me3(OMe)tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
A10	0.00	0.00	39.79	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg t- AmOH: 100.00 uL
G10	0.00	0.00	40.15	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
D9	8.40	0.00	40.26	(tBu)PhCPhos Pd G4: 0.16 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
A8	0.00	0.00	40.51	t-BuOK: 2.24 mg MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
C12	9.07	0.00	41.23	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
B12	2.56	0.00	41.45	Gphos Pd G3: 0.18 mg T- BuOK: 2.24 mg t-AmOH: 100.00 uL
E6	6.42	0.00	41.67	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
D12	0.00	0.00	41.75	Gphos Pd G3: 0.18 mg KHMDS: 3.99 mg t-

				AmOH: 100.00 uL
G6	0.00	0.00	41.98	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H1	0.00	0.00	42.23	Me3(OMe)tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
E11	0.00	0.00	42.40	BrettPhos Pd G3: 0.18 mg Cs2CO3: 6.52 mg t- AmOH: 100.00 uL
B5	2.27	0.00	42.59	Pd PEPPSI Ipr: 0.14 mg t- BuOK: 2.24 mg dioxane: 100.00 uL
H11	0.00	0.00	42.71	Pd PEPPSI Ipr: 0.14 mg P2- Et: 6.66 uL t-AmOH: 100.00 uL
C9	0.00	0.00	44.16	JosiPhos Pd G3: 0.19 mg KHMDS: 3.99 mg t- AmOH: 100.00 uL
A12	7.38	0.00	44.62	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg t- AmOH: 100.00 uL
E8	0.00	0.00	45.86	Cs2CO3: 6.52 mg MorDalPhos Pd G4: 0.17 mg t-AmOH: 100.00 uL
H12	3.66	0.00	47.14	Gphos Pd G3: 0.18 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
C1	0.00	0.00	47.69	Ad-BippyPhos: 0.13 mg KHMDS: 3.99 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
B8	0.00	0.00	49.38	AdBrettPhos Pd G3: 0.20 mg t-BuOK: 2.24 mg t- AmOH: 100.00 uL
E5	0.00	0.00	50.29	BrettPhos Pd G3: 0.18 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
F3	0.00	0.00	51.15	(tBu)PhCPhos Pd G4: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
F6	0.00	0.00	51.51	Gphos Pd G3: 0.18 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL

D4	0.00	0.00	51.79	PhCPhos: 0.08 mg KHMDS: 3.99 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
A11	0.00	0.00	54.00	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
E4	0.00	0.00	54.97	tBuBrettPhos Pd G3: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
B1	1.27	0.00	56.81	Me3(OMe)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C3	2.93	0.00	57.81	JosiPhos Pd G3: 0.19 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D3	0.00	0.00	58.08	(tBu)PhCPhos Pd G4: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
F8	0.00	0.00	58.26	AdBrettPhos Pd G3: 0.20 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
G2	0.00	0.00	58.85	P2-Et: 6.66 uL MorDalPhos Pd G4: 0.17 mg dioxane: 100.00 uL
C4	0.00	0.00	59.15	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C2	0.00	0.00	61.07	KHMDS: 3.99 mg MorDalPhos Pd G4: 0.17 mg dioxane: 100.00 uL
G1	1.12	0.00	63.25	Ad-BippyPhos: 0.13 mg P2-Et: 6.66 uL DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL
D10	0.00	0.00	63.63	PhCPhos: 0.08 mg KHMDS: 3.99 mg DMPDAB Pd MAH: 0.09 mg t-AmOH: 100.00 uL
A4	0.00	0.00	64.65	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
E1	3.69	0.00	64.68	Ad-BippyPhos: 0.13 mg Cs2CO3: 6.52 mg DMPDAB Pd MAH: 0.09 mg dioxane: 100.00 uL

A5	0.00	0.00	65.13	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B2	0.00	0.00	67.34	AdBrettPhos Pd G3: 0.20 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F1	0.00	0.00	71.04	Me3(OMe)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
A2	2.13	0.00	100.00	t-BuOK: 2.24 mg MorDalPhos Pd G4: 0.17 mg dioxane: 100.00 uL

Buchwald-Hartwig secondary amine and aniline screening kit (secondary amine)

Cell ID	Desired Product (%)	Reactant (%)	Components
	tert-butyl 4-{1H-pyrrolo[2,3-b]pyridin-5-yl}piperazine-1-carboxylate Max Resp:375059.5 m/z:303	5-bromo-1H-pyrrolo[2,3-b]pyridine Max Resp:194346.0 m/z:197	
C3	100.00	41.97	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL KHMDS: 3.99 mg dioxane: 100.00 uL
C5	88.80	49.35	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C4	83.17	27.68	RuPhos Pd G4: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
A7	82.72	27.60	Qphos Pd G3: 0.22 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C6	73.81	43.75	tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D3	73.61	37.70	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C1	70.66	34.88	Qphos Pd G3: 0.22 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D2	70.06	33.19	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL

C7	68.42	34.29	Qphos Pd G3: 0.22 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D4	65.26	47.87	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
B12	59.47	30.62	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C2	54.67	55.07	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C10	53.91	48.63	RuPhos Pd G4: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D1	53.58	42.85	P(tBu)3 Pd G4: 0.11 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D12	53.54	29.49	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D5	51.66	54.34	Ephos Pd G4: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D6	47.18	46.61	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
A5	45.10	60.25	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A1	41.12	40.94	Qphos Pd G3: 0.22 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B1	38.87	73.90	P(tBu)3 Pd G4: 0.11 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A12	35.57	31.99	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C12	31.18	32.08	tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
A11	25.69	41.10	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B9	24.84	35.14	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D9	22.17	43.02	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B7	20.50	43.65	P(tBu)3 Pd G4: 0.11 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
D10	18.04	0.00	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B10	17.04	37.68	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24

			mg t-AmOH: 100.00 uL
C11	17.01	43.32	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B6	10.46	38.77	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A6	9.54	24.93	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B2	6.48	100.00	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B4	3.55	74.22	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A4	3.52	7.55	RuPhos Pd G4: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
G4	0.00	38.35	RuPhos Pd G4: 0.17 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G5	0.00	51.15	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G6	0.00	54.40	tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G7	0.00	29.67	Qphos Pd G3: 0.22 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
G8	0.00	35.26	Pd PEPPSI Ipr: 0.14 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
G9	0.00	24.55	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL P2-Et: 6.66 uL t-AmOH: 100.00 uL
G10	0.00	35.56	RuPhos Pd G4: 0.17 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
G11	0.00	30.41	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
G12	0.00	34.17	tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H1	0.00	31.56	P(tBu)3 Pd G4: 0.11 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H2	0.00	60.56	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H3	0.00	29.83	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg P2-Et: 6.66 uL dioxane: 100.00 uL

H4	0.00	36.62	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H5	0.00	34.23	Ephos Pd G4: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H6	0.00	42.34	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H7	0.00	37.07	P(tBu)3 Pd G4: 0.11 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H8	0.00	30.38	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H9	0.00	22.05	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H10	0.00	42.85	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H11	0.00	39.78	Ephos Pd G4: 0.18 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H12	0.00	25.73	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
A2	0.00	31.07	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A3	0.00	22.80	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL t-BuOK: 2.24 mg dioxane: 100.00 uL
A8	0.00	11.62	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A9	0.00	8.05	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A10	0.00	5.63	RuPhos Pd G4: 0.17 mg T-BuOK: 2.24 mg t-AmOH: 100.00 uL
B3	0.00	65.03	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B5	0.00	62.86	Ephos Pd G4: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B8	0.00	40.15	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B11	0.00	50.07	Ephos Pd G4: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL

C8	0.00	61.45	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
C9	0.00	45.26	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL KHMDS: 3.99 mg t-AmOH: 100.00 uL
D7	0.00	32.23	P(tBu)3 Pd G4: 0.11 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D8	0.00	15.10	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D11	0.00	0.00	Ephos Pd G4: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
E1	0.00	0.00	Qphos Pd G3: 0.22 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E2	0.00	63.51	Pd PEPPSI Ipr: 0.14 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E3	0.00	0.00	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL Cs2CO3: 6.52 mg dioxane: 100.00 uL
E4	0.00	38.07	RuPhos Pd G4: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E5	0.00	59.68	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E6	0.00	53.00	tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E7	0.00	9.39	Qphos Pd G3: 0.22 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E8	0.00	39.45	Pd PEPPSI Ipr: 0.14 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E9	0.00	40.68	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E10	0.00	47.19	RuPhos Pd G4: 0.17 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E11	0.00	48.44	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E12	0.00	43.76	tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
F1	0.00	37.48	P(tBu)3 Pd G4: 0.11 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
F2	0.00	58.84	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg Cs2CO3:

			6.52 mg dioxane: 100.00 uL
F3	0.00	37.87	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F4	0.00	48.89	tBuBrettPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F5	0.00	50.87	Ephos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F6	0.00	60.68	BrettPhos Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F7	0.00	30.67	P(tBu) ₃ Pd G4: 0.11 mg Cs ₂ CO ₃ : 6.52 mg t- AmOH: 100.00 uL
F8	0.00	56.88	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F9	0.00	16.28	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F10	0.00	26.53	tBuBrettPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F11	0.00	15.00	Ephos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg t- AmOH: 100.00 uL
F12	0.00	34.37	BrettPhos Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
G1	0.00	49.59	Qphos Pd G3: 0.22 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G2	0.00	52.99	Pd PEPPSI Ipr: 0.14 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G3	0.00	40.54	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatran: 0.07 uL P2- Et: 6.66 uL dioxane: 100.00 uL

Buchwald secondary amine and aniline screening kit (aniline)

Cell ID	Desired Product (%)	Reactant (%)	Components
	5-methoxy-N-{1H-pyrrolo[2,3-b]pyridin-5-yl}pyridin-2-amine	5-bromo-1H-pyrrolo[2,3-b]pyridine	
	Max Resp:328926.2	Max Resp:58428.6	
	m/z:241	m/z:197	

B6	100.00	0.00	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C11	84.74	0.00	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
B10	81.60	0.00	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B4	75.29	6.97	tBuBrettPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A1	49.71	28.59	Qphos Pd G3: 0.22 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B12	44.81	3.63	BrettPhos Pd G3: 0.18 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C12	33.48	27.47	tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
E12	27.75	33.94	tBuXPhos Pd G3: 0.16 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
A12	25.74	3.65	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
C4	23.89	37.25	RuPhos Pd G4: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
B1	22.86	1.96	P(tBu) ₃ Pd G4: 0.11 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
D4	18.23	35.51	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg dioxane: 100.00 uL
F12	13.76	50.01	BrettPhos Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
A5	10.62	96.50	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F4	8.28	49.22	tBuBrettPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
B7	4.31	47.64	P(tBu) ₃ Pd G4: 0.11 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
E11	4.26	31.42	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
D10	4.22	40.55	tBuBrettPhos Pd G3: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
A4	4.16	58.39	RuPhos Pd G4: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A11	3.95	64.06	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A2	0.00	59.99	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24

			mg dioxane: 100.00 uL
A3	0.00	39.25	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL t-BuOK: 2.24 mg dioxane: 100.00 uL
A6	0.00	77.72	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
A7	0.00	29.50	Qphos Pd G3: 0.22 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A8	0.00	55.71	Pd PEPPSI Ipr: 0.14 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A9	0.00	65.64	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL t-BuOK: 2.24 mg t-AmOH: 100.00 uL
A10	0.00	42.06	RuPhos Pd G4: 0.17 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B2	0.00	34.85	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B3	0.00	38.68	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B5	0.00	61.91	Ephos Pd G4: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B8	0.00	51.81	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B9	0.00	42.28	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg t-BuOK: 2.24 mg t-AmOH: 100.00 uL
B11	0.00	39.82	Ephos Pd G4: 0.18 mg T-BuOK: 2.24 mg t-AmOH: 100.00 uL
C1	0.00	84.76	Qphos Pd G3: 0.22 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C2	0.00	41.75	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C3	0.00	42.96	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL KHMDS: 3.99 mg dioxane: 100.00 uL
C5	0.00	68.80	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
C6	0.00	41.57	tBuXPhos Pd G3: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL

C7	0.00	52.30	Qphos Pd G3: 0.22 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
C8	0.00	65.56	Pd PEPPSI Ipr: 0.14 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
C9	0.00	47.51	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL KHMDS: 3.99 mg t-AmOH: 100.00 uL
C10	0.00	58.86	RuPhos Pd G4: 0.17 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D1	0.00	48.75	P(tBu)3 Pd G4: 0.11 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D2	0.00	44.05	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D3	0.00	38.24	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D5	0.00	27.77	Ephos Pd G4: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D6	0.00	56.81	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg dioxane: 100.00 uL
D7	0.00	41.96	P(tBu)3 Pd G4: 0.11 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D8	0.00	33.70	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D9	0.00	52.31	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D11	0.00	65.17	Ephos Pd G4: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
D12	0.00	0.00	BrettPhos Pd G3: 0.18 mg KHMDS: 3.99 mg t-AmOH: 100.00 uL
E1	0.00	54.63	Qphos Pd G3: 0.22 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E2	0.00	31.24	Pd PEPPSI Ipr: 0.14 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E3	0.00	40.30	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E4	0.00	41.19	RuPhos Pd G4: 0.17 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL

E5	0.00	34.23	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E6	0.00	52.27	tBuXPhos Pd G3: 0.16 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E7	0.00	46.44	Qphos Pd G3: 0.22 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
E8	0.00	30.78	Pd PEPPSI Ipr: 0.14 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
E9	0.00	30.61	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
E10	0.00	42.64	RuPhos Pd G4: 0.17 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F1	0.00	97.00	P(tBu) ₃ Pd G4: 0.11 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F2	0.00	97.91	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F3	0.00	39.56	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F5	0.00	48.86	Ephos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F6	0.00	71.74	BrettPhos Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F7	0.00	39.51	P(tBu) ₃ Pd G4: 0.11 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F8	0.00	33.56	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F9	0.00	19.25	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F10	0.00	48.38	tBuBrettPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
F11	0.00	100.00	Ephos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
G1	0.00	40.68	Qphos Pd G3: 0.22 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G2	0.00	45.31	Pd PEPPSI Ipr: 0.14 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G3	0.00	60.02	DMPDAB Pd MAH: 0.09

			mg Triisobutylphosphatrane: 0.07 uL P2-Et: 6.66 uL dioxane: 100.00 uL
G4	0.00	69.49	RuPhos Pd G4: 0.17 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G5	0.00	28.81	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G6	0.00	34.06	tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
G7	0.00	30.20	Qphos Pd G3: 0.22 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
G8	0.00	28.83	Pd PEPPSI Ipr: 0.14 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
G9	0.00	57.23	DMPDAB Pd MAH: 0.09 mg Triisobutylphosphatrane: 0.07 uL P2-Et: 6.66 uL t-AmOH: 100.00 uL
G10	0.00	37.03	RuPhos Pd G4: 0.17 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
G11	0.00	8.94	[Pd(bippyPhos)(allyl)]OTf: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
G12	0.00	25.50	tBuXPhos Pd G3: 0.16 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
H1	0.00	34.66	P(tBu)3 Pd G4: 0.11 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H2	0.00	43.98	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H3	0.00	52.60	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H4	0.00	67.22	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H5	0.00	17.49	Ephos Pd G4: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H6	0.00	32.09	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL dioxane: 100.00 uL
H7	0.00	49.79	P(tBu)3 Pd G4: 0.11 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
H8	0.00	32.74	DMPDAB Pd MAH: 0.09 mg Brett/Ru/JackiePhos: 0.16 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H9	0.00	34.61	DMPDAB Pd MAH: 0.09 mg Brett/C/JackiePhos: 0.15 mg P2-Et: 6.66

			uL t-AmOH: 100.00 uL
H10	0.00	13.34	tBuBrettPhos Pd G3: 0.17 mg P2-Et: 6.66 uL t-AmOH: 100.00 uL
H11	0.00	44.97	Ephos Pd G4: 0.18 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL
H12	0.00	55.14	BrettPhos Pd G3: 0.18 mg P2-Et: 6.66 uL t- AmOH: 100.00 uL

Buchwald amide and oxygen screening kit (amide)

Cell ID	Desired Product (%)	Reactant (%)	Components
	N-(4-methoxyphenyl)pyridine-3-carboxamide	NICOTINAMIDE (BT1703, N)	
	Max Resp:1890096.0	Max Resp:462573.8	
	m/z:229	m/z:123	
C7	100.00	5.95	AdBrettPhos-Pd-G3: 0.20 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
D10	76.86	5.68	RockPhos Pd G3: 0.17 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
C8	76.43	5.97	AdBrettPhos-Pd-G3: 0.20 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
D11	61.11	11.95	RockPhos Pd G3: 0.17 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
A8	60.16	9.04	K3PO4: 4.25 mg tBuBrettPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
D5	53.43	40.87	RockPhos Pd G3: 0.17 mg K3PO4: 4.25 mg dioxane: 100.00 uL
A1	48.33	28.33	Cs2CO3: 6.52 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
G8	48.00	41.05	Me3(Ome)tBuXPhos Pd G3: 0.16 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
F7	30.31	50.45	tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
B8	29.27	64.04	K3PO4: 4.25 mg 4MetBuXPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
A2	27.09	23.07	K3PO4: 4.25 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
D4	23.96	23.35	RockPhos Pd G3: 0.17 mg Cs2CO3:

			6.52 mg dioxane: 100.00 uL
C2	22.39	22.84	AdBrettPhos-Pd-G3: 0.20 mg K3PO4: 4.25 mg dioxane: 100.00 uL
B7	21.42	40.13	Cs2CO3: 6.52 mg 4MetBuXPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
A11	18.08	74.14	BrettPhos Pd G4: 0.18 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
F8	16.39	36.04	tBuXPhos Pd G3: 0.16 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
F10	14.54	98.04	TrixiePhos Pd G3: 0.15 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
A9	13.41	63.75	KOAc: 1.96 mg tBuBrettPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
A5	12.91	52.13	BrettPhos Pd G4: 0.18 mg K3PO4: 4.25 mg dioxane: 100.00 uL
A4	11.11	33.31	BrettPhos Pd G4: 0.18 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
C9	8.12	58.23	AdBrettPhos-Pd-G3: 0.20 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
F11	7.38	46.62	TrixiePhos Pd G3: 0.15 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
A7	6.35	77.36	Cs2CO3: 6.52 mg tBuBrettPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
C1	6.20	21.60	AdBrettPhos-Pd-G3: 0.20 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
D12	6.00	52.77	RockPhos Pd G3: 0.17 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
G10	5.18	65.15	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
G1	4.64	22.05	Me3(Ome)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
A10	3.99	34.45	BrettPhos Pd G4: 0.18 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
G9	3.28	77.64	Me3(Ome)tBuXPhos Pd G3: 0.16 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
E4	2.74	38.26	JosiPhos Pd G3: 0.19 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
H11	2.72	36.80	Pd(allyl)Otf-BippyPhos: 0.16 mg K3PO4: 4.25 mg t-AmOH: 100.00

			uL
A3	2.26	41.67	KOAc: 1.96 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
B9	2.24	60.71	KOAc: 1.96 mg 4MetBuXPhos Pd G3: 0.17 mg t-AmOH: 100.00 uL
G11	2.05	48.82	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
H5	2.04	29.59	Pd(allyl)Otf-BippyPhos: 0.16 mg K3PO4: 4.25 mg dioxane: 100.00 uL
G2	1.77	28.00	Me3(Ome)tBuXPhos Pd G3: 0.16 mg K3PO4: 4.25 mg dioxane: 100.00 uL
C3	1.66	36.73	AdBrettPhos-Pd-G3: 0.20 mg KOAc: 1.96 mg dioxane: 100.00 uL
F12	1.64	44.28	TrixiePhos Pd G3: 0.15 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
H4	1.61	57.46	Pd(allyl)Otf-BippyPhos: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
F2	1.58	22.13	tBuXPhos Pd G3: 0.16 mg K3PO4: 4.25 mg dioxane: 100.00 uL
B2	1.54	36.46	K3PO4: 4.25 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
G7	1.53	36.06	Me3(Ome)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
F5	1.48	67.22	TrixiePhos Pd G3: 0.15 mg K3PO4: 4.25 mg dioxane: 100.00 uL
E5	1.32	42.46	JosiPhos Pd G3: 0.19 mg K3PO4: 4.25 mg dioxane: 100.00 uL
F1	1.29	26.48	tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
D6	1.27	65.55	RockPhos Pd G3: 0.17 mg KOAc: 1.96 mg dioxane: 100.00 uL
F4	1.17	54.49	TrixiePhos Pd G3: 0.15 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
F3	1.08	46.13	tBuXPhos Pd G3: 0.16 mg KOAc: 1.96 mg dioxane: 100.00 uL
H12	0.97	54.09	Pd(allyl)Otf-BippyPhos: 0.16 mg KOAc: 1.96 mg t-AmOH: 100.00 uL

B1	0.80	29.59	Cs ₂ CO ₃ : 6.52 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
G4	0.65	53.49	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
H8	0.62	45.69	Xphos Pd G4: 0.17 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 100.00 uL
E8	0.56	43.70	JackiePhos Pd G3: 0.23 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 100.00 uL
A6	0.00	48.88	BrettPhos Pd G4: 0.18 mg KOAc: 1.96 mg dioxane: 100.00 uL
A12	0.00	62.08	BrettPhos Pd G4: 0.18 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
B3	0.00	46.65	KOAc: 1.96 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
B4	0.00	63.09	XantPhos Pd G4: 0.19 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
B5	0.00	53.48	XantPhos Pd G4: 0.19 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
B6	0.00	56.24	XantPhos Pd G4: 0.19 mg KOAc: 1.96 mg dioxane: 100.00 uL
B10	0.00	74.00	XantPhos Pd G4: 0.19 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
B11	0.00	45.87	XantPhos Pd G4: 0.19 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 100.00 uL
B12	0.00	57.90	XantPhos Pd G4: 0.19 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
C4	0.00	66.57	DPPF Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
C5	0.00	58.17	DPPF Pd G3: 0.18 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
C6	0.00	66.79	DPPF Pd G3: 0.18 mg KOAc: 1.96 mg dioxane: 100.00 uL
C10	0.00	45.56	DPPF Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg t-AmOH: 100.00 uL
C11	0.00	43.68	DPPF Pd G3: 0.18 mg K ₃ PO ₄ : 4.25 mg t-AmOH: 100.00 uL
C12	0.00	49.35	DPPF Pd G3: 0.18 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
D1	0.00	23.74	rac-BINAP Pd G4: 0.20 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL

D2	0.00	32.29	rac-BINAP Pd G4: 0.20 mg K3PO4: 4.25 mg dioxane: 100.00 uL
D3	0.00	43.94	rac-BINAP Pd G4: 0.20 mg KOAc: 1.96 mg dioxane: 100.00 uL
D7	0.00	96.62	rac-BINAP Pd G4: 0.20 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
D8	0.00	47.65	rac-BINAP Pd G4: 0.20 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
D9	0.00	71.27	rac-BINAP Pd G4: 0.20 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
E1	0.00	61.27	JackiePhos Pd G3: 0.23 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
E2	0.00	25.26	JackiePhos Pd G3: 0.23 mg K3PO4: 4.25 mg dioxane: 100.00 uL
E3	0.00	35.17	JackiePhos Pd G3: 0.23 mg KOAc: 1.96 mg dioxane: 100.00 uL
E6	0.00	56.99	JosiPhos Pd G3: 0.19 mg KOAc: 1.96 mg dioxane: 100.00 uL
E7	0.00	75.57	JackiePhos Pd G3: 0.23 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E9	0.00	74.46	JackiePhos Pd G3: 0.23 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
E10	0.00	72.04	JosiPhos Pd G3: 0.19 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
E11	0.00	53.16	JosiPhos Pd G3: 0.19 mg K3PO4: 4.25 mg t-AmOH: 100.00 uL
E12	0.00	66.35	JosiPhos Pd G3: 0.19 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
F6	0.00	54.66	TrixiePhos Pd G3: 0.15 mg KOAc: 1.96 mg dioxane: 100.00 uL
F9	0.00	0.00	tBuXPhos Pd G3: 0.16 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
G3	0.00	27.29	Me3(Ome)tBuXPhos Pd G3: 0.16 mg KOAc: 1.96 mg dioxane: 100.00 uL
G5	0.00	64.45	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg K3PO4: 4.25 mg dioxane: 100.00 uL
G6	0.00	38.86	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg KOAc: 1.96 mg dioxane: 100.00 uL
G12	0.00	51.31	DMPDAB-Pd-MAH: 0.09

			mg tBuMePhos: 0.06 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
H1	0.00	22.23	Xphos Pd G4: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
H2	0.00	33.75	Xphos Pd G4: 0.17 mg K3PO4: 4.25 mg dioxane: 100.00 uL
H3	0.00	40.40	Xphos Pd G4: 0.17 mg KOAc: 1.96 mg dioxane: 100.00 uL
H6	0.00	42.53	Pd(allyl)Otf-BippyPhos: 0.16 mg KOAc: 1.96 mg dioxane: 100.00 uL
H7	0.00	37.87	Xphos Pd G4: 0.17 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL
H9	0.00	68.48	Xphos Pd G4: 0.17 mg KOAc: 1.96 mg t-AmOH: 100.00 uL
H10	0.00	100.00	Pd(allyl)Otf-BippyPhos: 0.16 mg Cs2CO3: 6.52 mg t-AmOH: 100.00 uL

Buchwald amide and oxygen screening kit (oxygen)

Cell ID	Desired Product (%)	Reactant (%)	Components
	tert-butyl 3-(quinolin-6-yloxy)azetidine-1-carboxylate	tert-butyl 3-hydroxyazetidine-1-carboxylate	
	Max Resp:730117.8	Max Resp:0.0	
	m/z:301	m/z:174	
G1	100.00	0.00	Me3(Ome)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg toluene: 100.00 uL
B1	91.17	0.00	Cs2CO3: 6.52 mg 4MetBuXPhos Pd G3: 0.17 mg toluene: 100.00 uL
A1	74.79	0.00	Cs2CO3: 6.52 mg tBuBrettPhos Pd G3: 0.17 mg toluene: 100.00 uL
D5	65.13	0.00	RockPhos Pd G3: 0.17 mg K3PO4: 4.25 mg toluene: 100.00 uL
A2	62.43	0.00	K3PO4: 4.25 mg tBuBrettPhos Pd G3: 0.17 mg toluene: 100.00 uL
H5	49.59	0.00	Pd(allyl)Otf-BippyPhos: 0.16 mg K3PO4: 4.25 mg toluene: 100.00

			uL
F10	44.99	0.00	TrixiePhos Pd G3: 0.15 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
A4	34.18	0.00	BrettPhos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
F1	31.84	0.00	tBuXPhos Pd G3: 0.16 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
C2	31.07	0.00	AdBrettPhos-Pd-G3: 0.20 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
E1	29.38	0.00	JackiePhos Pd G3: 0.23 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
C1	19.63	0.00	AdBrettPhos-Pd-G3: 0.20 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
H11	18.69	0.00	Pd(allyl)Otf-BippyPhos: 0.16 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
A7	14.09	0.00	Cs ₂ CO ₃ : 6.52 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
G8	14.02	0.00	Me ₃ (Ome)tBuXPhos Pd G3: 0.16 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
B7	13.95	0.00	Cs ₂ CO ₃ : 6.52 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
D11	13.16	0.00	RockPhos Pd G3: 0.17 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
E10	11.82	0.00	JosiPhos Pd G3: 0.19 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
F4	8.81	0.00	TrixiePhos Pd G3: 0.15 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
E2	8.17	0.00	JackiePhos Pd G3: 0.23 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
E5	6.93	0.00	JosiPhos Pd G3: 0.19 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
A5	6.38	0.00	BrettPhos Pd G4: 0.18 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
H1	5.27	0.00	Xphos Pd G4: 0.17 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
F2	3.96	0.00	tBuXPhos Pd G3: 0.16 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
H4	3.40	0.00	Pd(allyl)Otf-BippyPhos: 0.16

			mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
F7	3.10	0.00	tBuXPhos Pd G3: 0.16 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
C8	2.90	0.00	AdBrettPhos-Pd-G3: 0.20 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
G2	2.77	0.00	Me ₃ (Ome)tBuXPhos Pd G3: 0.16 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
C7	2.68	0.00	AdBrettPhos-Pd-G3: 0.20 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
A8	2.64	0.00	K ₃ PO ₄ : 4.25 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
A3	2.12	0.00	t-BuOK: 2.24 mg tBuBrettPhos Pd G3: 0.17 mg toluene: 100.00 uL
A6	2.02	0.00	BrettPhos Pd G4: 0.18 mg t-BuOK: 2.24 mg toluene: 100.00 uL
D12	1.98	0.00	RockPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
G4	1.95	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
G11	1.92	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
B8	1.92	0.00	K ₃ PO ₄ : 4.25 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
B2	1.90	0.00	K ₃ PO ₄ : 4.25 mg 4MetBuXPhos Pd G3: 0.17 mg toluene: 100.00 uL
D4	1.85	0.00	RockPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
D1	1.45	0.00	rac-BINAP Pd G4: 0.20 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
G10	1.44	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
A9	0.00	0.00	t-BuOK: 2.24 mg tBuBrettPhos Pd G3: 0.17 mg dioxane: 100.00 uL
A10	0.00	0.00	BrettPhos Pd G4: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
A11	0.00	0.00	BrettPhos Pd G4: 0.18 mg K ₃ PO ₄ :

			4.25 mg dioxane: 100.00 uL
A12	0.00	0.00	BrettPhos Pd G4: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
B3	0.00	0.00	t-BuOK: 2.24 mg 4MetBuXPhos Pd G3: 0.17 mg toluene: 100.00 uL
B4	0.00	0.00	XantPhos Pd G4: 0.19 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
B5	0.00	0.00	XantPhos Pd G4: 0.19 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
B6	0.00	0.00	XantPhos Pd G4: 0.19 mg t-BuOK: 2.24 mg toluene: 100.00 uL
B9	0.00	0.00	T-BuOK: 2.24 mg 4MetBuXPhos Pd G3: 0.17 mg dioxane: 100.00 uL
B10	0.00	0.00	XantPhos Pd G4: 0.19 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
B11	0.00	0.00	XantPhos Pd G4: 0.19 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
B12	0.00	0.00	XantPhos Pd G4: 0.19 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C3	0.00	0.00	AdBrettPhos-Pd-G3: 0.20 mg t-BuOK: 2.24 mg toluene: 100.00 uL
C4	0.00	0.00	DPPF Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
C5	0.00	0.00	DPPF Pd G3: 0.18 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
C6	0.00	0.00	DPPF Pd G3: 0.18 mg t-BuOK: 2.24 mg toluene: 100.00 uL
C9	0.00	0.00	AdBrettPhos-Pd-G3: 0.20 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
C10	0.00	0.00	DPPF Pd G3: 0.18 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
C11	0.00	0.00	DPPF Pd G3: 0.18 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
C12	0.00	0.00	DPPF Pd G3: 0.18 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
D2	0.00	0.00	rac-BINAP Pd G4: 0.20 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
D3	0.00	0.00	rac-BINAP Pd G4: 0.20 mg t-BuOK: 2.24 mg toluene: 100.00 uL
D6	0.00	0.00	RockPhos Pd G3: 0.17 mg t-BuOK: 2.24 mg toluene: 100.00 uL

D7	0.00	0.00	rac-BINAP Pd G4: 0.20 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
D8	0.00	0.00	rac-BINAP Pd G4: 0.20 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
D9	0.00	0.00	rac-BINAP Pd G4: 0.20 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
D10	0.00	0.00	RockPhos Pd G3: 0.17 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E3	0.00	0.00	JackiePhos Pd G3: 0.23 mg t-BuOK: 2.24 mg toluene: 100.00 uL
E4	0.00	0.00	JosiPhos Pd G3: 0.19 mg Cs ₂ CO ₃ : 6.52 mg toluene: 100.00 uL
E6	0.00	0.00	JosiPhos Pd G3: 0.19 mg t-BuOK: 2.24 mg toluene: 100.00 uL
E7	0.00	0.00	JackiePhos Pd G3: 0.23 mg Cs ₂ CO ₃ : 6.52 mg dioxane: 100.00 uL
E8	0.00	0.00	JackiePhos Pd G3: 0.23 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
E9	0.00	0.00	JackiePhos Pd G3: 0.23 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
E11	0.00	0.00	JosiPhos Pd G3: 0.19 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
E12	0.00	0.00	JosiPhos Pd G3: 0.19 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F3	0.00	0.00	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg toluene: 100.00 uL
F5	0.00	0.00	TrixiePhos Pd G3: 0.15 mg K ₃ PO ₄ : 4.25 mg toluene: 100.00 uL
F6	0.00	0.00	TrixiePhos Pd G3: 0.15 mg t-BuOK: 2.24 mg toluene: 100.00 uL
F8	0.00	0.00	tBuXPhos Pd G3: 0.16 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
F9	0.00	0.00	tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
F11	0.00	0.00	TrixiePhos Pd G3: 0.15 mg K ₃ PO ₄ : 4.25 mg dioxane: 100.00 uL
F12	0.00	0.00	TrixiePhos Pd G3: 0.15 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
G3	0.00	0.00	Me ₃ (Ome)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg toluene: 100.00 uL

G5	0.00	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg K3PO4: 4.25 mg toluene: 100.00 uL
G6	0.00	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg t-BuOK: 2.24 mg toluene: 100.00 uL
G7	0.00	0.00	Me3(Ome)tBuXPhos Pd G3: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
G9	0.00	0.00	Me3(Ome)tBuXPhos Pd G3: 0.16 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
G12	0.00	0.00	DMPDAB-Pd-MAH: 0.09 mg tBuMePhos: 0.06 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
H2	0.00	0.00	Xphos Pd G4: 0.17 mg K3PO4: 4.25 mg toluene: 100.00 uL
H3	0.00	0.00	Xphos Pd G4: 0.17 mg t-BuOK: 2.24 mg toluene: 100.00 uL
H6	0.00	0.00	Pd(allyl)Otf-BippyPhos: 0.16 mg t- BuOK: 2.24 mg toluene: 100.00 uL
H7	0.00	0.00	Xphos Pd G4: 0.17 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
H8	0.00	0.00	Xphos Pd G4: 0.17 mg K3PO4: 4.25 mg dioxane: 100.00 uL
H9	0.00	0.00	Xphos Pd G4: 0.17 mg t-BuOK: 2.24 mg dioxane: 100.00 uL
H10	0.00	0.00	Pd(allyl)Otf-BippyPhos: 0.16 mg Cs2CO3: 6.52 mg dioxane: 100.00 uL
H12	0.00	0.00	Pd(allyl)Otf-BippyPhos: 0.16 mg t- BuOK: 2.24 mg dioxane: 100.00 uL

S_NAr screening kit

Cell ID	Desired Product (%)	Reactant (%)	Components
	methyl 7-(benzyloxy)- 1H-indazole-4- carboxylate	1H-INDAZOLE-4-CARBOXYLIC ACID, 7-FLUORO-, METHYL ESTER (BT301412,FRIDGE F)	
	Max Resp:365728.1	Max Resp:429213.8	

	m/z:281	m/z:193	
F10	100.00	1.31	CsF: 0.60 mg KHMDS: 7.98 mg NMP: 100.00 uL
F1	59.54	0.00	No ligand: 0.00 mg KHMDS: 7.98 mg DMF: 100.00 uL
F9	5.63	0.00	No ligand: 0.00 mg KHMDS: 7.98 mg NMP: 100.00 uL
F2	3.93	4.65	CsF: 0.60 mg KHMDS: 7.98 mg DMF: 100.00 uL
H1	1.94	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg DMF: 100.00 uL
F7	1.38	0.00	No ligand: 0.00 mg KHMDS: 7.98 mg DMSO: 100.00 uL
H2	1.01	2.09	CsF: 0.60 mg T-BuOK: 4.49 mg DMF: 100.00 uL
A1	0.00	100.00	No ligand: 0.00 mg NEt3: 5.56 uL DMF: 100.00 uL
A10	0.00	27.72	CsF: 0.60 mg NEt3: 5.56 uL NMP: 100.00 uL
A11	0.00	90.52	No ligand: 0.00 mg NEt3: 5.56 uL CPME: 100.00 uL
A12	0.00	48.05	CsF: 0.60 mg NEt3: 5.56 uL CPME: 100.00 uL
A2	0.00	15.56	CsF: 0.60 mg NEt3: 5.56 uL DMF: 100.00 uL
A3	0.00	11.85	No ligand: 0.00 mg NEt3: 5.56 uL MeCN: 100.00 uL
A4	0.00	7.28	CsF: 0.60 mg NEt3: 5.56 uL MeCN: 100.00 uL
A5	0.00	73.52	No ligand: 0.00 mg NEt3: 5.56 uL t-AmOH: 100.00 uL
A6	0.00	46.35	CsF: 0.60 mg NEt3: 5.56 uL t- AmOH: 100.00 uL
A7	0.00	48.12	No ligand: 0.00 mg NEt3: 5.56 uL DMSO: 100.00 uL

A8	0.00	26.24	CsF: 0.60 mg NEt3: 5.56 uL DMSO: 100.00 uL
A9	0.00	74.50	No ligand: 0.00 mg NEt3: 5.56 uL NMP: 100.00 uL
B1	0.00	8.13	No ligand: 0.00 mg DBU: 5.97 uL DMF: 100.00 uL
B10	0.00	7.01	CsF: 0.60 mg DBU: 5.97 uL NMP: 100.00 uL
B11	0.00	35.35	No ligand: 0.00 mg DBU: 5.97 uL CPME: 100.00 uL
B12	0.00	41.44	CsF: 0.60 mg DBU: 5.97 uL CPME: 100.00 uL
B2	0.00	11.65	CsF: 0.60 mg DBU: 5.97 uL DMF: 100.00 uL
B3	0.00	7.10	No ligand: 0.00 mg DBU: 5.97 uL MeCN: 100.00 uL
B4	0.00	5.73	CsF: 0.60 mg DBU: 5.97 uL MeCN: 100.00 uL
B5	0.00	34.54	No ligand: 0.00 mg DBU: 5.97 uL t-AmOH: 100.00 uL
B6	0.00	25.16	CsF: 0.60 mg DBU: 5.97 uL t-AmOH: 100.00 uL
B7	0.00	5.27	No ligand: 0.00 mg DBU: 5.97 uL DMSO: 100.00 uL
B8	0.00	5.72	CsF: 0.60 mg DBU: 5.97 uL DMSO: 100.00 uL
B9	0.00	24.94	No ligand: 0.00 mg DBU: 5.97 uL NMP: 100.00 uL
C1	0.00	7.21	No ligand: 0.00 mg TMG: 5.02 uL DMF: 100.00 uL
C10	0.00	3.72	CsF: 0.60 mg TMG: 5.02 uL NMP: 100.00 uL
C11	0.00	32.31	No ligand: 0.00 mg TMG: 5.02 uL CPME: 100.00 uL
C12	0.00	6.17	CsF: 0.60 mg TMG: 5.02 uL CPME: 100.00 uL
C2	0.00	1.80	CsF: 0.60 mg TMG: 5.02 uL DMF: 100.00 uL
C3	0.00	5.44	No ligand: 0.00 mg TMG: 5.02 uL MeCN: 100.00 uL
C4	0.00	6.64	CsF: 0.60 mg TMG: 5.02

			uL MeCN: 100.00 uL
C5	0.00	51.14	No ligand: 0.00 mg TMG: 5.02 uL t-AmOH: 100.00 uL
C6	0.00	19.78	CsF: 0.60 mg TMG: 5.02 uL t-AmOH: 100.00 uL
C7	0.00	6.08	No ligand: 0.00 mg TMG: 5.02 uL DMSO: 100.00 uL
C8	0.00	4.58	CsF: 0.60 mg TMG: 5.02 uL DMSO: 100.00 uL
C9	0.00	10.91	No ligand: 0.00 mg TMG: 5.02 uL NMP: 100.00 uL
D1	0.00	50.69	No ligand: 0.00 mg DIPEA: 6.97 uL DMF: 100.00 uL
D10	0.00	26.08	CsF: 0.60 mg DIPEA: 6.97 uL NMP: 100.00 uL
D11	0.00	34.54	No ligand: 0.00 mg DIPEA: 6.97 uL CPME: 100.00 uL
D12	0.00	34.17	CsF: 0.60 mg DIPEA: 6.97 uL CPME: 100.00 uL
D2	0.00	21.84	CsF: 0.60 mg DIPEA: 6.97 uL DMF: 100.00 uL
D3	0.00	25.80	No ligand: 0.00 mg DIPEA: 6.97 uL MeCN: 100.00 uL
D4	0.00	6.78	CsF: 0.60 mg DIPEA: 6.97 uL MeCN: 100.00 uL
D5	0.00	34.01	No ligand: 0.00 mg DIPEA: 6.97 uL t-AmOH: 100.00 uL
D6	0.00	29.41	CsF: 0.60 mg DIPEA: 6.97 uL t-AmOH: 100.00 uL
D7	0.00	23.00	No ligand: 0.00 mg DIPEA: 6.97 uL DMSO: 100.00 uL
D8	0.00	38.42	CsF: 0.60 mg DIPEA: 6.97 uL DMSO: 100.00 uL
D9	0.00	47.48	No ligand: 0.00 mg DIPEA: 6.97 uL NMP: 100.00 uL
E1	0.00	33.77	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg DMF: 100.00 uL
E10	0.00	67.12	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg NMP: 100.00 uL
E11	0.00	0.00	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg CPME: 100.00 uL

E12	0.00	6.04	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg CPME: 100.00 uL
E2	0.00	42.28	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg DMF: 100.00 uL
E3	0.00	3.02	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg MeCN: 100.00 uL
E4	0.00	4.09	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg MeCN: 100.00 uL
E5	0.00	6.22	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg t-AmOH: 100.00 uL
E6	0.00	7.57	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg t-AmOH: 100.00 uL
E7	0.00	47.25	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg DMSO: 100.00 uL
E8	0.00	25.87	CsF: 0.60 mg Cs ₂ CO ₃ : 13.03 mg DMSO: 100.00 uL
E9	0.00	42.39	No ligand: 0.00 mg Cs ₂ CO ₃ : 13.03 mg NMP: 100.00 uL
F11	0.00	1.28	No ligand: 0.00 mg KHMDS: 7.98 mg CPME: 100.00 uL
F12	0.00	0.00	CsF: 0.60 mg KHMDS: 7.98 mg CPME: 100.00 uL
F3	0.00	0.00	No ligand: 0.00 mg KHMDS: 7.98 mg MeCN: 100.00 uL
F4	0.00	0.00	CsF: 0.60 mg KHMDS: 7.98 mg MeCN: 100.00 uL
F5	0.00	0.00	No ligand: 0.00 mg KHMDS: 7.98 mg t-AmOH: 100.00 uL
F6	0.00	0.00	CsF: 0.60 mg KHMDS: 7.98 mg t-AmOH: 100.00 uL
F8	0.00	0.00	CsF: 0.60 mg KHMDS: 7.98 mg DMSO: 100.00 uL
G1	0.00	50.40	No ligand: 0.00 mg K ₃ PO ₄ : 8.49 mg DMF: 100.00 uL
G10	0.00	42.58	CsF: 0.60 mg K ₃ PO ₄ : 8.49 mg NMP: 100.00 uL
G11	0.00	4.56	No ligand: 0.00 mg K ₃ PO ₄ : 8.49 mg CPME: 100.00 uL
G12	0.00	2.03	CsF: 0.60 mg K ₃ PO ₄ : 8.49 mg CPME: 100.00 uL
G2	0.00	54.16	CsF: 0.60 mg K ₃ PO ₄ : 8.49

			mg DMF: 100.00 uL
G3	0.00	1.40	No ligand: 0.00 mg K3PO4: 8.49 mg MeCN: 100.00 uL
G4	0.00	5.03	CsF: 0.60 mg K3PO4: 8.49 mg MeCN: 100.00 uL
G5	0.00	5.56	No ligand: 0.00 mg K3PO4: 8.49 mg t-AmOH: 100.00 uL
G6	0.00	0.00	CsF: 0.60 mg K3PO4: 8.49 mg t- AmOH: 100.00 uL
G7	0.00	70.33	No ligand: 0.00 mg K3PO4: 8.49 mg DMSO: 100.00 uL
G8	0.00	41.70	CsF: 0.60 mg K3PO4: 8.49 mg DMSO: 100.00 uL
G9	0.00	66.47	No ligand: 0.00 mg K3PO4: 8.49 mg NMP: 100.00 uL
H10	0.00	0.00	CsF: 0.60 mg T-BuOK: 4.49 mg NMP: 100.00 uL
H11	0.00	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg CPME: 100.00 uL
H12	0.00	0.00	CsF: 0.60 mg T-BuOK: 4.49 mg CPME: 100.00 uL
H3	0.00	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg MeCN: 100.00 uL
H4	0.00	0.00	CsF: 0.60 mg T-BuOK: 4.49 mg MeCN: 100.00 uL
H5	0.00	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg t-AmOH: 100.00 uL
H6	0.00	0.00	CsF: 0.60 mg T-BuOK: 4.49 mg t- AmOH: 100.00 uL
H7	0.00	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg DMSO: 100.00 uL
H8	0.00	0.00	CsF: 0.60 mg T-BuOK: 4.49 mg DMSO: 100.00 uL
H9	0.00	0.00	No ligand: 0.00 mg T-BuOK: 4.49 mg NMP: 100.00 uL